Welcome

Asterias Biotherapeutics

AST’s offering is priced at $3.90 per share <size not disclosed>. Concurrently, AST entered into a private placement for the sale of common stock at the same price as the underwritten public offering. Gross proceeds to AST from the public offering and the private placement are expected to be approximately $5.5 M in the aggregate. Closing of the public offering is scheduled for 2/10/15 subject to customary closing conditions. MLV & Co. LLC is acting as the Sole Book-Running Manager for the offering. AST closed <Wednesday, 2/4/15> at $3.90 and was DOWN -$0.30 or -7.69% to $3.60 on 23.96 K share volume <3 month = 30.46 K>. Surprised at the size although its parent - BioTime (NYSEMKT: BTX) never busts the "bubble" of financing! Let it settle and watch the share price ... "wander" before jumping in - the real question ... "where's the data from advancing clinicals"? HOLD

Hold

Athersys, Inc.

Athersys (ATHX) – Plunders and pillages investor “interests” as it’s BOD rewards FY14 share depreciation and clinical “significance” of <MultiStem ® failed trial> Pfizer (PFE)sponsored trial. Bonuses are a GROSS failure of oversight, governance and transparency. A big dependence on one platform for multiple disease indications and stroke is the hardest of all. Pricing is "blowin' in the wind" SELL

Sell

AxoGen, Inc.

AXGN priced an underwritten public offering of 4,728,000 shares of its common stock, offered at a price to the public of $2.75 per share. The gross proceeds to AxoGen from this offering are expected to be approximately $13 M, before deductions. AxoGen has granted the underwriter an option to purchase up to an additional 709,200 shares during the next 30 days. Wedbush PacGrow Life Sciences is acting as sole manager for the offering. AXGN closed at $3.45 and is DOWN -$0.50 or -14.49% to $2.95 <2/5/14> on 389 share volume <3 month = 61.7 shares>. The drop of $0.5o and a $0.25 discount is more than BIG as a combination of an expected downturn and a significant … discount! Even as AXGN set the expectation of Q4/14 revenue of $4.79 M, a 61% increase compared to revenue of $2.98 M in Q4/13. For the full year 2014, AXGN’s revenue is expected to be $16.8 M, representing a 54% increase compared to revenue of $10.9 M for FY14. I like this company, until it settles - HOLD!

Hold

Brainstorm Cell Therapeutics Inc.

BrainStorm (BCLI) had announced pre-clinical results in Mouse Autism Model – in which I promptly said - SELL into strengths and speculation. Animal models “anticipate” VERY early results and “good” science has to start somewhere however, in BCLI’s own words it exhibited “several … stereotypical behavioral characteristics”. I am NOT sure that is ... enough. BCLI is UP +$0.43 or +11.25% to $4.25 in the pre-market. Enjoy the ride. A mouse has autism? Speculation and anticipation runs rampant; let it jump as speculators will in turn take it DOWN as fast as it goes UP. NurOwn™ cells are mesenchymal stem cells (MSCs) that have been ... induced to secrete a variety of neurotrophic factor ... along with the stock. BCLI has been “strolling” downward since the 1/27/15 after the announcement which I questioned! On 2/5/15, BCLI is DOWN -$0.05 to $3.78 – a long way from 1/2/15’s $7.50. SELL

Sell

Bioheart, Inc.

The P1 safety and preliminary efficacy of adipose derived stem cells (AdipoCell™) in patients with congestive heart failure measures safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months. BHRT closed flat 10/10/14 at $0.02 and remains FLAT in Monday morning’s trading session. Why it is even PUBLIC – to feed from the market trough?

Sell

Bellicum Pharmaceuticals, Inc.

Bellicum (BLCM), a new addition to RMi’s list of covered companies After an IPO on 12/18/14raised $140 M on sale of 7.35 M shares at $19 each <above its $15-$17 expected range>, BLCM had risen to $31.75 but, has dropped down to $22.27 <2/7/15>. Immunotherapy involves removing blood cells from a patient, programming those cells to recognize and then attack cancer cells, and then replacing those blood cells in the patient. Not only is there greater efficacy vs. traditional chemotherapy, but side effects are reduced. BLCM's pipeline includes BPX-401, which uses targeting mechanisms called chimeric antigen receptors (CARs) to train T cells to bind to the CD19 antigen, expressed by hematological cancer cells. Following that is BPX-601, a CAR-T candidate that targets solid tumors, and BPX-701, an immunotherapy for skin cancer. Each of BLCM's CAR-T candidates uses technology derived from a T cell therapy designed to ward off graft-versus-host disease in patients undergoing stem cell transplants which also comes with a "safety switch" … “it says” can mute unwanted transplant reactions like cytokine release syndrome, a common response to CAR-T therapy that has occasionally proven fatal in early studies, including those conducted by Juno (JUNO) and rival Novartis (NVS).BLCM plans to submit rolling IND filings for each, starting in the second half of 2015 and continuing into 2016. BLCM has suffered the effects of profit taking post the IPO. HOLD

Hold

BioLife Solutions, Inc.

BLFS provided an update on the adoption in an increased number of customer clinical trials of novel cellular immunotherapies and other cell-based approaches. In 2014, BLFS expanded product adoption by several very promising profile companies…BLFS estimated that BioLife products were incorporated in clinical processes and protocols of 100 regenerative medicine clinical trials…For the calendar year 2014, management estimates that an additional 75 regenerative medicine clinical trials using BioLife products were confirmed, bringing the total to 175… BLFS’s addressable share of this market is attributed to the demand for biopreservation media and controlled temperature shipping containers. BLFS is positioned to participate in the growth of the regenerative medicine market and the cellular immunotherapy segment of oncology care. BioLife is an embedded technology story, with biopreservation media products part of customer processes.

Buy

Bluebird Bio

bluebird bio (BLUE) is DOWN and UP and DOWN again and again. Shares of BLUE surged following the receipt of a Breakthrough Therapy designation. BLUE’s pricing surge has been weakening as the day and weeks evolved. Traders are eating away at the pricing while venture investors and executives are selling <the usual tax issues>. The strengths are still there but have been blurred in the short-term by selling while investor excitement over these therapies have helped boost interest and have fueled a jump in share prices of BLUE. I am a strong believer – investors are spooked by VC <rotational> and insider <planned> sales - HOLD to BUY

Buy

BioRestorative Therapies, Inc.

The “doors” stay opened for BRTX, a VERY early development stage company. TOO low to say sell and NOT “enough” of a development platform to even consider a buy. – HOLD

Hold

BioTime, Inc.

BTX raised $29.4 M in a direct offering consisting of 9,431,398 shares at $3.12 per share. Certain BTX subsidiaries also sold 504.5 K shares of BTX that they held. BTX and its subsidiaries that sold BTX shares will use the proceeds to finance the usual initiatives including clinical trials of products under development, R&R, and for general working capital corporate purpose. I still NEED convincing on the business structure and its inter-dependency! This company NEVER holds its gains!

Hold

Capricor

Capricor Therapeutics (OTCBB: CAPR), has signed definitive agreements for the sale of approximately $7 M to select investors at a price of $4.25 per share after <1/12/15> inking a $10 M private placement agreement of company stock at $3.52 per share. The common stock financing includes participation from Cedars-Sinai Medical Center, CureDuchenne Ventures LLC, and several CAPR directors and officers. The second “deal” in a week of common stock financing includes participation from Broadfin Capital, LLC, Sabby Capital, LLC. H.C. Wainwright and SC&H Capital were placement agents for the financing. The combination of financing rounds <$10 M raised on 1/12/15> now adds approximately $17 M in cash to its balance sheet increasing its shareholders equity to what they believe meets … NASDAQ listing requirements. CAPR has been trending UP and then DOWN and UP again on low to moderate <for them> having commenced the year at $3.75. Before jumping in, let the share price settle – HOLD.

Hold

Neuralstem, Inc.

On 10/9/14, CUR announced it treated its first patient in its P1 trial testing NSI-566 human neural stem cells in the treatment of chronic spinal cord injury (cSCI) at the UC San Diego School of Medicine. The NSI-566/cSCI EARLY P1 “safety and efficacy” study will treat 4 patients who have thoracic spinal cord injuries (T2-T12) with stem cell transplants directly into the region of the injury, between one and two years post-injury. All of the patients have an American Spinal Injury Association (AIS) grade A level of impairment -- complete paralysis with no motor or sensory function in the relevant segments at and below the injury. You never know about CUR – round and round – a rubric cube of trading with too many questions! SELL

Sell

Cytori Therapeutics, Inc.

CYTX received final approval for an Investigational Device Exemption (IDE). The approval allows CYTX to begin a clinical trial (STAR) to evaluate Cytori Cell Therapy as a potential treatment for impaired hand function in scleroderma. The STAR trial will begin enrolling in 2015 and will include 80 patients in up to 12 centers in the U.S. It will evaluate the safety and efficacy of a single administration of CYTX’s cellular therapeutic, ECCS-50, in scleroderma patients with hand dysfunction. Plusses are resonating however; CYTX’s current debt situation, hedge fund holdings i.e. overhang and downward pricing interferes with its future. The best part- there is no expectation – SELL to HOLD, if you own it;

Hold

Fate Therapeutics, Inc.

FATE filed a $100 M mixed securities shelf consisting of up to $100 M of an indeterminate amount of common stock, preferred stock, debt securities, warrants and/or units.

Hold

Fibrocell Science, Inc.

FCSC CFO Gregory Weaver resigned effective immediately. A reason for Weaver’s departure was not given. Kimberly Smith, FCSC’s controller will serve as interim CFO, treasurer, and corporate secretary until a successor is named

Hold

Harvard Apparatus

Harvard Apparatus RT (HART) backtracked on timelines with more “ifs” on clinical operations. HART will need ... NOW additional development and testing within its ongoing preclinical large-animal model testing of the HART-Trachea. HART believes that the additional testing needed is readily achievable, however, it estimates that this testing will require an additional 2 to 6 months beyond the previous estimates. The submission of the application for Clinical Trial Authorization, or CTA, with the Medicines and Healthcare Products Regulatory Agency, or MHRA, of the U.K. and the IND, with the FDA is expected to take place in the first half of 2016 rather than by the end of 2015. MY question is and has been … what is the clinical advantage supporting “their” pillars of share pricing! HART will run-out of money by July 2015 … IF they don’t raise money. Be ready for the discount and dilution if HART is even able to re-capitalize in this market with questions re the trachea. The multiple and revolving issues of Dr. Paolo Macchiarini as part of the HART-Trachea product ongoing airway transplant studies have been … shut down with HART needing to complete the pre-clinical work necessary to initiate clinical trials in the EU and U.S. HART has been in a decline since 1/2/15’s close of $3.44 and then jumping to $3.93 on 1/7/15 but, has been downhill since then with declining volume. A FAR cry … from the $10.45 on 6/30/14 or even the $11.00 on 3/1/14 … after HART’s initiation of a “sponsored” program of broker outreach having started FY14 <1/2/14> with a price of $4.61 … seen now as a backfiring and negative perception stimulus <i.e. peaking the share price to let it fall disastrously>. IS … Harvard Apparatus (HART) - quietly ... in the market for a $4 M retail oriented offering … to keep the company “afloat” and the “wolves away from the door”. How could companies with such … potential have performed so awfully? Although, CEOs have in the past … hit a ball out of the park … they do strike out eading to huge losses for their investors … when they can’t or won’t listen to those who want to help, assist and partner! A very risky business based on too many assumptions - SELL.

Sell

Histogenics Corporation

Histogenics (HSGX), a new addition to RMi’s roster, closed at $11.00 (the offering price) on 12/8/14. The offering was FLAT and hedge buyers will be selling after NO big pop! I’ve been saying it would dip – a one product shot on goal, dangerous – SELL;

Sell

Cellular Dynamics

ICEL was awarded a $1.2 M contract by the National Eye Institute (NEI - a division of the NIH) to manufacture clinically-compatible induced pluripotent stem cells (IPSCs) and iSPC-derived human retinal epithelial (RPE) cells. The cells will be manufactured from individuals suffering from dry age-related macular degeneration (AMD) and will be used for investigational new drug (IND) enabling studies. HOLD UNTIL POST EARNINGS.

Hold

ImmunoCellular Therapeutics, Ltd.

IMUC signed an agreement with the California Institute of Technology (Caltech) that gives IMUC exclusive rights to technology for the development of antigen-specific, T-cell immunotherapies for the treatment of cancer. The technology, from the labs of David Baltimore, PhD, Nobel Laureate and President Emeritus, and Robert Andrews, Millikan Professor of Biology at Caltech, uses patient hematopoietic stem cells to create antigen-specific killer T-cells to treat cancer. But with terms of the agreement not disclosed, it makes me wonder if IMUC is just using the Caltech and David Baltimore’s name in a move to bring share price to over $1.00?

Hold

International Stem Cell Corporation

ISCO’s Parkinson’s program continues to progress on the plan developed with input from the FDA. To date no adverse events or pathological reactions have been observed in any of the completed preclinical pharmacology/toxicology studies. Results from these studies will form the basis of the regulatory submission requesting authorization to administer the drug in humans that ISCO expects to submit prior to the end of the year. The complete preclinical dataset will be presented at the Society for Neuroscience annual meeting on 11/18/14. Once final steps in the preclinical development program are complete, ISCO will submit an IND and, with the regulatory agency's approval, begin the P1/2 safety and efficacy clinical trial.

Hold

Juno Therapeutics, Inc.

On 12/18/2014 JUNO, a new addition to RMi’s list of covered companies, priced its IPO above the expected range offering 11 M shares at $24.00 raising $265 M. In less than 1 month, its price ... had SKYROCKETED +55% to $52.80 as of 1/8/15. JUNO has been weathering the profiteering storm post the IPO that like a meteor "blaised" the sky .. and has fallen to the $40.00's. JUNO has 10 clinical candidates moving into the clinic next year while promising to change the standard of care for blood cancers. JUNO's candidates are CAR-T immunotherapies, made through a process in which scientists remove T cells from a patient's blood and equip them with targeting mechanisms called chimeric antigen receptors (CARs), which seek out and bind to proteins expressed by cancer cells. The resulting cells are re-injected into the patient, at which point they track down malignancies and attack them as they would any commonplace infection. Juno's lead candidate, JCAR015, is a treatment for acute lymphoblastic leukemia (ALL), the stellar PI results of which led the FDA to grant a breakthrough therapy designation, promising an expedited regulatory review. Behind that is JCAR017, in development for ALL and non-Hodgkin lymphoma (NHL), followed by JCAR014, which is undergoing early studies on various B cell malignancies. JUNO recently expanded its pipeline by licensing another CAR-T candidate developed by the National Cancer Institute and currently in PI development for ALL and NHL. JUNO's closest competitor is Novartis (NVS), which is developing a similarly promising PI CAR-T therapy alongside the University of Pennsylvania. Competitors include Kite Pharma (KITE), which grossed more than $140 M in a June IPO on the strength of its approach to T cell modification, and oncology heavyweight Celgene (CELG), which reached out to gene therapy pioneer bluebird bio (BLUE) to get to work in CAR-T. JUNO has plenty of work ahead before can get in front of regulators; but it is the next generation of sustaining life and potential approvals - BUY

Buy

Kite Pharma, Inc.

KITE is a new addition to RMi’s list of covered companies. Kite Pharma (KITE) also made its IPO debut. KITE had offered 7.5 M shares at $17 each raising $128 M having pricing well above its range of $12 to $14. KITE is focused on engineered autologous T cell therapies (eACT), which are intended to spur the immune system to attack cancer cells. It's working on the technology under a cooperative research agreement with the National Cancer Institute's surgery branch, aiming to advance a host of targeted and personalized treatments for a variety of cancers. KITE’s lead program uses chimeric antigen receptors to reprogram a patient's T cells and transform them into cancer-fighting agents, called CAR-T immunotherapies and its lead program, KTE-C19, targets CD19-positive B cell cancers, including diffuse large-B cell lymphoma (DLBCL), an aggressive subtype of non-Hodgkin lymphoma. KITE snapped up the NIH's IP on TCRs that target the NY-ESO-1 antigen which is implicated in a variety of cancers. TCR technology looks to genetically reengineer T cells into cancer-fighting soldiers, opening a new chapter in immuno-oncology (IO) that has quickly grabbed the attention of some key players in the cancer arena. TCRs are focused on intracellular tinkering, and NY-ESO-1 looks to be the top contender among the targets for treating tumors. KITE agreed to pay the NIH a set of milestones and royalties for any successful program without spell out the details. KITE plans a PI/II study on the drug in 2015 and use the results to apply for an accelerated FDA approval that would clear 'C19 for use as a third-line treatment for patients with DLBCL. On 1/5/15, KITE and Amgen (AMGN) inked a research and licensing agreement that focuses on development and commercialization of Chimeric Antigen Receptor (CAR) T cell immunotherapies based on KITE’s engineered autologous cell therapy (eACT™) platform and AMGN's extensive array of cancer targets. KITE will receive from AMGN an upfront payment of $60 M, as well as funding for R&D costs through IND filing. KITE will be eligible to receive up to $525 M in milestone payments per AMGN program based on the successful completion of regulatory and commercialization milestones, plus tiered high single- to double-digit royalties for sales and the license of KITE's intellectual property for CAR T cell products. KITE also has been granted orphan drug status for its Chimeric Antigen Receptor (CAR) T cell therapy (KTE-C19) for treatment of diffuse large B cell lymphoma (DLBCL). Lately <February> t’s been all about dips that will be followed by rebounds. Traders have been lightening their “load” while KITE is trading in a GOOD range of $60 to $64 range <having reached a high of $87.62> - BUY

Buy

Cesca Therapeutics, Inc

Recently, the FDA did NOT approve Cesca Therapeutics' (NASDAQ:KOOL) investigational device exemption (IDE) application to begin a 224-patient Phase 3 study assessing its SurgWerks-CLI and VXP system for the treatment of critical limb ischemia (CLI). However ... the FDA noted no deficiencies relating to KOOL's overall trial design, including the patient population size of 224, the 3:1 randomization and the use of a blinded independent committee for determination of amputation decisions. KOOL’s rejection may not be bad – FDA has to and NEEDS to provide clear guidance on why rejected and defines clear path forward. Back and forth in the pricing “arena’ but, has “nailed” the NASDAQ listing staying over a dollar but, a financing is needed. I like the team! The key is who will step-up in the financing … and what “event oriented” trial particulars need to come clear? HOLD

Hold

Mesoblast Limited

On 10/13, MBLTY announced it will spend up to $100 M buying a suite of patents in the US which have the potential to deliver revenues sooner than expected. The purchase brings with it two products already in their final stage of clinical trials with approvals for launch in Canada and New Zealand, and with the potential to win clearance for launch in the key US market within two years.

Sell

MiMedx Group, Inc

MiMedx (MDXG): Preliminary revenue exceeds Q4/14 and FY/14 guidance. MDXG revenue for FY/14 was $118.2 M, a $59.0 M or 100% increase over FY/13; making it the 3rd consecutive year revenue exceeded the upper-end of guidance. For Q4/14, MDXG saw record revenue of $39.6 M, a $21.6 million or 120% increase over Q4/13, making it the 13th consecutive quarter of meeting or exceeding revenue guidance. MDXG has voluntarily withdrawn its tortious interference lawsuit against Organogenesis, Inc., without prejudice. MDXG continues to believe that Organogenesis has engaged in misconduct against MiMedx. However, MDXG has determined that, rather than expend its time and resources in a protracted litigation with Organogenesis at this juncture. MDXG's efforts are better spent continuing its investigation into the Organogenesis activities against MiMedx involving not only the Veterans Administration but also other governmental agencies as well as MiMedx customers. MDXG reported its BOD increased authorization for its share repurchase plan from $10 M to $20 M. MDXG is up, down round and round but at $8.25 is a BUY

Buy

Neostem, Inc.

NeoStem (NBS) strengthened its executive management team – David J. Mazzo, PhD as CEO and Robert S. Vaters as President and CFO and elects Dr. Robin Smith to Executive Chair of the Board. I am reserving my judgment on the “event” due to the numerous personalities and the “oversight” involved in this decision that forced the BOD to initiate and facilitate the change in leadership. If there’s “blood on the street”, there’s also “blood on the hands” of those who put the CEO and BOD in a “defensible and warranted” position <in reaction> to both a tough year for an oversold share pricing from the results from NBS’s PreSERVE AMI P2 trial which some have labeled “disappointing”.

Hold

Nuo Therapeutics

CMXI is changing its name to Nuo Therapeutics. The change is part of a “strategic direction initiated by management earlier this year”. Yesterday, CMXI changed the name of its chronic wound treatment to Aurix®. Will new names help “resuscitate” a “shallow breather”? Going where - SELL

Sell

Northwest Biotherapeutics, Inc.

NWBO recently completed recruitment in its P1 trial of DCVax. War of words between NWBO and TheStreet.com seems to be abating. 10/2/14 CHANGE FROM BUY TO HOLD

Hold

Ocata Therapeutics, Inc.

Ocata (OTC: OCAT) ... formerly Advanced Cell (OTC: ACTC) seems unable to complete a 10 M share offering as DEMAND is just NOT there! Management <it has been rumored> is unable to accept a $4.00 share price. Says a LOT about the receptivity of the company after all that rumple of the past! The question remains ... does a leopard change its spots? Too much, NOT well timed and NOT enough! Is a "short "trap" about to be sprung? Cash position is dwindling with all those new hires - how much of $30 M Lincoln Park equity line is still available and for how long? OCAT is a “cult’ driven day-trader focused equity and trades by momentum initiatives (3 month volume = 128.5 K shares). It is a shame the new CEO had NOT been able to fulfill but, had he pushed the envelope without “conditioning” himself to the issues of the past and potential of the future. Never jump into a new “ballpark” without checking the mound, the base lines for “running room”! They deperately need a financing -SELL

Sell

Organovo Holdings, Inc.

It's been a wild ride, but things could still look bright for Organovo (ONVO)! Forget 3-D printing holograph; the real key for this investment is their developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research and therapeutic implants for the treatment of damaged or degenerating tissues and organs. ONVO is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting and nerve grafts for nerve damage repair, as well as functional tissue patches for the repair or replacement of damaged tissues and organs. ONVO enables the reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body. A 52 week trading range of 5.12 to $10.84 and a <3/5/15> day range of $6.02 to 46.16. Go with the trend as long as you’re on the right side of the trade. BUY

Buy

Opexa Therapeutic, Inc.

OPXA’s focus remains fixed on the execution of the P2b study of Tcelna™ (imilecleucel-T) in Secondary Progressive MS patients. Currently, the treatment options for these patients are very limited. In 2/13, OPXA secured an option and license agreement with Merck Serono that has potential of payments to OPXA that "could" total $225 M based upon the successful development and commercialization of Tcelna. OPXA initiated a rights offering; price to be between $0.65 and $0.75 per unit, redeemable if common stock closes above $2.50 per share for 10 consecutive trading days. Each right would entitle the holder to purchase one unit, composed of one share of common stock and a warrant to purchase one share of common stock, at a subscription price to be determined prior to the effective date of the registration statement; Opexa also intends to distribute the non-transferable subscription rights to holders of its Series L warrants who are entitled to participate in the rights offering pursuant to the terms of the warrants held by them. Shocked by the naming of the deal and co-dealer-manager for the rights offering! The sector needs to watch this one – concerning the capital market access window being open. Let's see who steps up for this transaction ... fast or faster money - first to sell and first to clip! Back to you, once the “deal’ is done - since the announcement the stock price has leveled at $0.72.

Hold

Osiris Therapeutics, Inc.

Osiris (OSIR) evokes the love and hate in various quarters and sessions. OSIR has deleted and expanded its management team throughout the year to be barely recognized. A major initiative was to enter into an exclusive, worldwide partnership with Stryker Corporation (SYK) for the commercialization and development of OSIR’s viable bone matrix tissue form. This partnership combines the strengths of Stryker’s orthopedic and spine products with OSIR’s cellular regenerative medicine viable bone matrix. The Agreement provides Stryker with exclusive, worldwide rights to Osiris’ viable bone matrix under the name BIO4 ™. BIO4 is a bone allograft that contains both viable cells and growth factors. It is a safe alternative to autografts that minimizes the potential for harvest site co-morbidities. BIO4 is composed of a structural extracellular matrix, osteogenic and angiogenic growth factors, endogenous mesenchymal stem cells and osteoblasts. It possesses osteo-conductive, osteo-inductive, osteogenic and angiogenic properties that are required for bone repair and regeneration. BIO4 was developed by Osiris and will now be marketed by Stryker under the brand name BIO4. OSIR “could” also lose its pass through status by the end of the year that could affect margins and revenue. I see both revenue and earnings growth although OSIR is a model of consistency though, as it has alternated beating and missing over each of its last six quarters yet consistently inconsistent but, better than the other 99.9% of other stem cell companies– BUY.

Buy

Pluristem Therapeutics, Inc.

Pluristem (PSTI) plays fast and loose … again shining a light on the abuse of their investor responsibilities. I had stated last week <1/29/15> that Pluristem (PSTI) Investors are or should be smarter re: a paid report to stimulate volume and “artificial” pricing. How could the “sponsored” report be considered … objective, they got paid for a beneficial view - a GREAT short position – SELL. Now, Bloomberg has jumped in the fray … “The <Acceleron> report shines a light on the often opaque world of research firms that drives shares of small-cap companies up and down. Investors don’t have enough information about Acceleron to judge its credibility, said Steven Tepper, a senior biomedical analyst at Migdal Capital Markets Ltd. in Tel Aviv. “It would be very irresponsible to make investment decisions on a research report that has no analyst name standing behind it,” he said, adding that his comments do not reflect his opinion about Pluristem. “We need to know who owns this research company, who are the managers, what is its business model. A disclaimer means nothing if there’s “no” analyst name written on the report.” PSTI came out this Monday (2/2/15> am with the … usual adjective laden press release extolling the hyperbole driven results of a P1/2 20 patient clinical trial of PLacental eXpanded (PLX-PAD) cells in the treatment of muscle injury after total hip arthroplasty (THA). PSTI’s share price has born the battering declining -$0-.88 since 1/30/15 - SELL

Sell

StemCells, Inc.

STEM launched its Pathway(R) study, a P2 proof of concept clinical trial using proprietary HuCNS-SC(R) platform of human neural stem cells for treatment of cervical spinal cord injury (SCI). It is the first clinical study designed to evaluate safety and efficacy of transplanting stem cells into patients with traumatic injury to the cervical spinal cord. The University Of Miami Miller School Of Medicine is the first site initiated into the Pathway study. The primary efficacy outcome will focus on change in upper extremity strength as measured in the hands, arms, and shoulders, and will follow the patients for 1 year from the time of enrollment.

Hold

Stemline Therapeutics, Inc.

STML recently filled its coofers with an offering of 3.8 M shares at $15.75 per share with gross proceeds tof $59.85 M. STML also exclusively licensed from CanBas Co., Ltd. the rights to develop and commercialize a novel, oral small molecule reversible inhibitor of Exportin-1 (XPO1), a nuclear transport target also known as Chromosomal Maintenance Region-1 (CRM1). Recent work has demonstrated that XPO1 is a clinically relevant target, and nuclear export inhibitors have emerged as a new approach in cancer treatment with activity in patients across multiple indications. STML floats with the wind and vagaries of the market and is … always a traders delight, never failing to satisfy the shorts – SELL

Sell

Vericel Corporation

Aastrom changed its name to Vericel Corporation and moved to Cambridge, Massachusetts. The name change … does NOT delete the “dubious’ history of Aastrom’s past. Q3/14 revenues were FLAT since the acquisition. Q4 might show an uptick as many “utilizers” cram their spending into the end-of-year. VCEL is faced with difficult and alternative issues - drive quarterly Carticel sales rate higher by driving more procedures while raising the price per implant – isn’t that counter-intuitive. How will users respond … the use of Carticel is heavily concentrated within a small number of orthopedic surgeons <it would be a negative to me>? Question still surround the use of Epicel and whether a comparable strategy should also be used? Elimination of sales reps and reduction of territories is NOT a good sign of progress and marketing/sales achievement and presupposes decrease in physician usage! VCEL halted sales of MACI™ in the EU <as the EU responded negatively to manufacturing and notification> and the company has supposedly a 3 year window in which to reintroduce the product without having to file for a new application <big question mark>. There are reimbursement challenges in Europe<based on their issues (again) of plant shut-down and notification>. MACI ™ is also going to need a … significant trial in the US … if any approvals are to be in the cards! I make the contention that … the elements of multiple competitive products … need to be factored into VCEL “actual” model! The acquisition has also entailed a ramp-up of new G&A and a reduction in S&M – while the size of the “corporates” rise, the number of the sales reps decrease and the RIF costs also wind down leaving an “institutional” history depleted! There was a reason why Sanofi (SNY) let the “unit” go! Credibility in the equity markets is based on believability and there are still a lot more questions in the INTERMEDIATE and LONG-TERM! Also, how long until “managing” or G&A costs out-weigh revenues and don’t forget the R&D and clinical costs of the next generation of products if they are even able to get them … approved in the US and EU. I have maintained a SELL

Sell

VistaGen Therapeutics, Inc.

The Canadian Intellectual Property Office has issued VSTA a Notice of Allowance for a patent entitled "Mesoderm and Definitive Endoderm Cell Populations”. This patent is licensed exclusively to VSTA by the Icahn School of Medicine at Mount Sinai in New York. Explain to me how a patent can be granted to VSTA when it does not own, but rather licenses the patent?

Hold

Verastem, Inc.

Verastem (VSTM) received an Orphan Medicinal Product Designation from EMA for VS-5584 in Mesothelioma. Under European Medicines Agency (EMA) guidelines, Orphan Medicinal Product Designation provides up to 10 years of market exclusivity if the product candidate is approved for marketing in the European Union and the orphan designation is maintained. Orphan status also permits EMA assistance in optimizing the candidate’s clinical development through participation in clinical trial design and preparation of the product marketing application. Additionally, a product candidate designated by the EMA as an Orphan Medicinal Product may qualify for a reduction in regulatory fees as well as a EU funded research grants. VSTM also recently closed an offering of 7.25 M shares of its common stock, offered at a price of $6.50 per share to the public. The net proceeds to Verastem from this offering are expected to be approximately $44.1 M, after deductions. VSTM had also granted to the underwriters a 30-day option to purchase up to 1,087,500 additional shares of common stock. Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers and Guggenheim Securities, LLC and Oppenheimer & Co. Inc. are acting as co-lead managers in the offering. A lot to say as VSTM was trading at $8.99 on 1/20/15, $9.34 on 1/12/15 and $9.45 on 1/2/15 – the vagaries of the market and issues of timing. VSTM has popped, dropped and bounced UP again <2/5/15> to $7.31 ... UP +$0.37 or +5.26% - BUY

Buy

Clear and Present Dangers

“Clear and Present Dangers” have become a public metaphor with various applications; mine involves the levels of executive compensation, salary, bonus, options, grants, payments for board participation and other bennies or reimbursed factors that investors have a RIGHT to … KNOW!

Skin-in-the-game

Indicators of insider holdings or “skin-in-the-game” should relate to management’s ownership defining belief, motivations and ability of any sector participant’s security and also is a signal, cue or even a prompt or call to action as investors review ... whether to act on an investment.

Governance & Transparency

Scoreboard

The Scorecard is a performance management tool which can be used by investors to keep track of the execution of activities and to monitor the consequences arising from these actions.

The characteristic of the Scorecard and its content is the presentation of a mixture of financial and non-financial measurements that should be compared to a 'target' value. The Scorecard is not meant to be a replacement for traditional financial or operational reports but a series of spreadsheets that captures succinct data and information relevant to those making investment decisions. The scorecard also gives light to the RegMed sector or company's not always considered metrics.

As a model of performance, the Scorecard is effective in that "it articulates the links between leading inputs, outcomes and focuses on the importance of those management processes to achieve a matrix for investors to measure performance versus priorities.

Submitted by Henry McCusker on December 10, 2013 - 12:47pm

“Cash is king" is an acute expression used in analyzing the RegMed universe to the importance of operating funds available in the development and trial process and the overall fiscal health of a business.

For investors it may also describe times when it is advantageous to understand capital market access and the resulting dilution and the availability of an investment opportunity.

COMPANY	SYMBOL	Q3/14 CASH (in millions)
Aastrom	ASTM	$37.6
Ocata (Formerly Advanced Cell)	OTC: OCTA	$7.8
Athersys	ATHX	$33.4
AxoGen	AXGN	$11.8
Bioheart	BHRT	$0.46
BioLife Solutions	BLFS	$11
BioRestorative	BRTX	$0.374
BioTime	BTX	$7.4
bluebird	BLUE	$215.4
Brainstorm	BCLI	$10.6
Capricor	CAPR	$10.6
Cellular Dynamics	ICEL	$41
CESCA	KOOL	$14.8
Nuo Therapeutics (formerly Cytomedix)	CMXI	$26
Cytori	CYTX	$20
Dendreon	DNDN	$107
FATE	FATE	$45.5
Fibrocell	NYSEMKT: FCSC	$44.2
Harvard Apparatus	HART	$7.7
ImmunoCellular	NYSEMKT: IMUC	$25
Int'l Stem Cell	OTC: ISCO	$0.47
MiMedx	MDXG	$47.2
NeoStem	NBS	$32.8
Neuralstem	NYSEMKT: CUR	$26.9
Northwest Bio	NWBO
Opexa	OPXA	$13.6
Organovo	NYSEMKT: ONVO	$54.4
Osiris	OSIR	$64
Pluristem	PSTI	$20
StemCells	STEM	$32.3
Stemline	STML	$44.5
Tengion	TNGN	$18.4
Verastem	VSTM	$93.3
VistaGen	VSTA	$0.40

Submitted by Henry McCusker on October 16, 2014 - 2:13pm

An earnings release is a ‘scorecard’ of sorts for a public regenerative medicine company.

The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position for a better snapshot! By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity of regenerative medicine research and whether or not it deserves their investment.

COMPANY	SYMBOL	Q3-14 LOSS	Q2-14 LPS	Q3/14 CASH
Aastrom	ASTM	-$6.9 M	-$0.52	$37.6 M
Ocata (formerly Advanced Cell)	(OTC: OCAT)	-$4.4 M	-$0.13	$7.8 M
Asterias	NYSEMKT: AST	-1.7 M	-$0.05	$5 M
Athersys	ATHX	-4.8 M	-$0.06	$33.4 M
AxoGen	AXGN	-3.3 M	-$0.19	$11.8 M
BioHeart	OTC: BHRT	-$1.5 M	-$0.03	$46.6 K
BioLife Solutions	BLFS	-$862 K	-$0.07	$11 M
BioRestorative	OTC: BRTX	-$1.1 M	-$0.04	$373.9 K
BioTime	NYSEMKT: BTX	-$10 M	-$0.12	$7.4 M
bluebird	BLUE	-$17 M	-$0.61	$215.4 M
Brainstorm	OTCBB: BCLI	-$2.4 M	-$0.16	$10.6 M
Capricor	CAPR	-$1.5 M	-$0.13	$10.6 M
Cellular Dynamics	ICEL	-$8.2 M	-$0.52	$41 M
Cesca	KOOL	(Q4) -3.29 M	(Q4) -$0.08	$14.8 M
Nuo Therapeutics (formerly Cytomedix)	OTC: NUOT	-$4.8 M	-$0.04	$20 M
Cytori	CYTX	-$9.4 M	-$0.12	$7.8 M
Dendreon - (bankrupt)	DNDN	-$22 M	-$0.14	$107 M
Fate	FATE	-6.6 M	-$0.32	$45.5 M
Fibrocell	NYSEMKT: FCSC	-$6 M	-$0.15	$44.2 M
Harvard Apparatus	HART	-$2.7 M	-$0.34	$7.7 M
ImmunoCellular	NYSEMKT: IMUC	-$1.9 M	-$0.03	$25 M
Int'l. Stem Cell	OTC: ISCO	-$2 M	-$0.01	$471 K
Mesoblast ADR	OTC: MBLTY
MiMedx	MDXG	+3.7 M	+$0.03	$47.2 M
NeoStem	NBS	-$17.2 M	-$0.48	$32.8 M
Neuralstem	NYSEMKT: CUR	-$4.5 M	-$0.05	$26.9 M
Northwest Bio	NWBO
Organovo (Q2/15)	NYSEMKT: ONVO	-8.9 M	-$0.11	$54.4 M
Opexa	OPXA	-$3.9 M	-$0.14	$13.6 M
Osiris	OSIR	+$61.5 K	+$0.02	$64 M
Pluristem	PSTI	-$5.9 M	-$0.09	$20 M
StemCells	STEM	-$2.8 M	-$0.04	$32.3 M
Stemline	STML	-$6.9 M	-$0.53	$44.5 M
Tengion	OTC: TNGN	-$18.4 M	-$.73	$4.7 M
Verastem	VSTM	-$13.3 M	-$0.53	$93.3 M
VistaGen	OTC: VSTA

Submitted by Henry McCusker on August 3, 2014 - 10:30pm

An earnings release is a ‘scorecard’ of sorts for a public regenerative medicine company.

COMPANY	SYMBOL	Q2-14 LOSS	Q2-14 LPS	Q2/14 CASH
Aastrom	ASTM	-$4.6 M	-$0.94	$7.3 M
Advanced Cell	OTC: ACTC	-$15.5 M	-$0.01	$4.1 M
Athersys	ATHX	+675 K	-$0.04	$38.7 M
AxoGen	AXGN	-3.7 M	$-0.21	$14.2 M
BioHeart	OTC: BHRT	-$451.4 K	-$0.001	$91.2 K
BioLife Solutions	BLFS	-$883 K	-$0.07	$11.9 M
BioRestorative	OTC: BRTX	-$1.3 M	-$0.06	$59.1 K
BioTime	NYSEMKT: BTX	-$11.4 M	-$0.16	$15.7 M
bluebird	BLUE	-$1.5 M	-$0.06	$175.7 M
Brainstorm	OTCBB: BCLI	-$4.1 M	-$0.02	$11.3 M
Capricor	CAPR	-$1.5 M	-$0.13	$12.0 M
Cellular Dynamics	ICEL	-$5.M	-$2.92	$47.4 M
Cesca	KOOL
Cytomedix	OTC: CMXI	-$11.3 M	-$0.09	$26.0 M
Cytori	CYTX	-$11.8 M	-$0.15	$12.8 M
Dendreon	DNDN	-$15.3 M	-$0.10	$127.0 M
Fate	FATE	-$6.1 M	-$0.30	$42.0 M
Fibrocell	NYSEMKT: FCSC	-$16.2 M	-$0.06	$49.5 M
Harvard Apparatus	HART	-$3 M	-$0.39	$10.0 M
ImmunoCellular	NYSEMKT: IMUC	-$3.1 M	-$0.05	$25.0 M
Int'l. Stem Cell	OTC: ISCO	-$4.4 M	-$0.03	$748.0 K
Mesoblast	OTC: MBLTY	-$81 M ($AUD) (FY-14)	NA	$196.4 M ($AUD) (FY-14)
MiMedx	MDXG	$390.1 K	$0.00	$39.2 M
NeoStem	NBS	-$12.7 M	-$0.40	$32.8 M
Neuralstem	NYSEMKT: CUR	-$6.7 M	-$0.08	$30.2 M
Northwest Bio	NWBO	-$25.9 M	-$0.45	$8.9 M
Organovo (Q1/15)	NYSEMKT: ONVO	-$6.4 M	-$0.08	$44.9 M
OPXA	OPXA	-$4.16 M	-$0.15	$16.2 M
Osiris	OSIR	-$1.88 M	-$0.05	$48.4 M
Pluristem	PSTI
StemCells	STEM	-$12.1 M	-$0.22	$17.8 M
Stemline	STML	-$6 M	-$0.47	$22.2 M
Tengion	OTC: TNGN	-$11.9 M	-$3.59 M	$21.5 M
Verastem	VSTM	-$13.0 M	-$0.51	$98.5 M
VistaGen	OTC: VSTA	-$4.6 M	-$0.19	$400.7 K

Submitted by Henry McCusker on May 17, 2014 - 1:31pm

An earnings release is a ‘scorecard’ of sorts for a public regenerative medicine company.

COMPANY	SYMBOL	Q1-14 LOSS	Q1-14 LPS	Q1/14 CASH
Aastrom	ASTM	-$6.0 M	-$1.26	$8.8 M
Advanced Cell	ACTC	-$8.7 M	$0.00	$45.0 M
Athersys	ATHX	-$11.5 M	-$0.15	$45.0 M
AxoGen	AXGN	-$4.2 M	-$0.24	$16.8 M
Bioheart	BHRT	+$677.4 K	+$0.001 diluted	$219.0 K
BioLife Solutions	BLFS	-$-559.3 K	-$0.10	$12.8 M
BioRestorative	BRTX
BioTime	BTX
bluebird	BLUE	-10.6 M	-$0.44	$192.5 M
Brainstorm	BCLI
Capricor	CAPR	-$1.2 M	-$0.10	$13.0 M
Cellular Dynamics	ICEL	-$5.7 M	-$3.28	$53.7 M
Cesca	KOOL	-$1.9 M	-$0.07	$6.6 M
Cytomedix	CMXI
Cytori	CYTX	-$10.4 M	-$0.14	$12.8 M
Dendreon	DNDN	-$36.4 M	-$0.24	$90.1 M
Fate	FATE	-$7.0 M	-$0.34	$47.8 M
Fibrocell	FCSC	-$14.0 M	-$0.35	$54.0 M
Harvard Apparatus	HART	-$3.0 M	-$0.39	$12.6 M
ImmunoCellular	IMUC	$-3.2 M	-$0.05	$25.0 M
Int'l. Stem Cell	ISCO	-$1.4 M	-$0.01	$991 K
Mesoblast	MBLTY
MiMedx	MDXG	-$922.1 M	-$0.01	$43.0 M
NeoStem	NBS	-$13.7 M	-$0.49	$41.4 M
Northwest Bio	NWBO
Organovo	ONVO
OPXA	OPXA	-$3.7 M	-$0.13	$19.7 M
Osiris	OSIR	-$1.36 M	-$0.04	$2.34 M
Pluristem	PSTI	-$20.7 M	-$0.14	$3.6 M
StemCells	STEM	-$7.6 M	-$0.14	$26.5 M
Stemline	STML
Tengion	TNGN	-$34.2 M	-$2.11	$15.4 M
Verastem	VSTM	-$13.0 M	-$0.51	$13.2 M
VistaGen	VSTA

Submitted by Henry McCusker on May 17, 2014 - 1:27pm

An earnings release is a ‘scorecard’ of sorts for a public regenerative medicine company.

COMPANY	SYMBOL	Q1 LOSS/LPS	Q1 CASH	Q2 LOSS/LPS	Q2 CASH	Q3 LOSS/LPS	Q3 CASH	Q4 LOSS/LPS	Q4 CASH
Aastrom	ASTM	-$7.2 M/-$3.00	$9.2 M	-$5.2 M/-$2.20	$4.5 M	-$3.6 M/-$0.06	$10.8 M	-2.9 M/-$0.97	$8.0 M
Advanced Cell	ACTC	-$6.4 M/$0.00	$4.1 M	-$6.6 M/$0.00	$5.5 M	-$6.3 M/$0.00	$5.5 M	-$12.8 M/$0.00	$1.7 M
Athersys	ATHX	-$9.3 M/-$0.18	$21.3 M	-$5.9 M/-$0.1	$18.9 M	-$5.6 M/-$0.1	$17.8 M	-$9.8 M/-$0.15	$32.0 M
AxoGen	AXGN	-$3.5 M/ -$.022	$22.4 M	-$3.6 M/-$0.22	$8.7 M	-$4.1 M/-$0.31	$22.6 M	-$4.2 M/-$0.31	$20.0 M
Bioheart	BHRT	-$519 K/$0.00	$239.0 K	-$750 K/-$0.01	$173 K	-$1.1 M/$0.00	$7.0 K	/-$727 K$0.00	$46.0 K
BioLife Solutions	BLFS	-$297.0 K/$0.00	$61.5 K	-$283 K/$0.00	$76.0 K	-$310 K/-$0.14	$79.0 K	-485.0 K/-$0.08	$156.0 K
BioRestorative	BRTX	-$1.6 M/-$0.01	$498.6 K	-$1.3 M/-$0.08	$0.00	-$1.3 M/-$0.07	$1.0 K	-$1.6 M/-$0.01	$201.0 K
BioTime	BTX	-$7.7 M/-$0.15	$9.9 M	-$19.6 M/-$0.14	$14.3 M	-9.0 M/-$0.16	$6.7 M	-$19.6 M/-$0.36	$5.5 M
bluebird	BLUE	-$6.5 M/-$19.94	NA	-$4.6 M/$11.00	$22.8 M	-$6.1 M/$6.98	$216.7 M	-$8.1 M/-$0.06	$206.0 M
Brainstorm	BCLI	-$1.1 M/-$0.05	$1.9 M	-$1.5 M/$0.04	$755.0 K	-$1.1 M/-$0.01	$429.0 K	-$1.2 M/-$0.01	$3.5 M
Capricor	CAPR	-483 K/-$0.50	$285.0 K	-$598 K/-$1.00	$$229.0 K	-$348 K/-0.00	$71.0 K	-$7.46 M/-$0.65	$3.1 M
Cellular Dynamics	ICEL	NA/-$3.28	NA	-$-5.0 M/-$2.92	$33.5 M	-$7.5 M/-$2.71	$68.6 M	-$6.7 M/-$0.32	$62.0 M
Cesca*	KOOL	-$1.1 M/-$0.06	$7.5 M	-$2.4 M/-$0.03	$6.9 M	-$2.3 M/-$0.07	$5.3 M	-$1.6 M/-$0.15	$2.3 M
Cytomedix	CMXI	$7.8 M/-$0.11	$7.2 M	-$3.2 M/-$0.05	$13.6 M	-$5.3 M/-$0.08	$10.2 M	-$10.0 M/$0.15	$15.5 M
Cytori	CYTX	-$7.8 M/-$.011	$16.4 M	-$3.2 M/-$0.05	$13.6 M	-$5.3 M/-$0.08	$10.2 M	-$10.0 M/-$0.15	$15.5 M
Dendreon	DNDN	-$72.0 M/-$0.48	$130.5 M	-$69.0 M/-$0.58	$92.0 M	-$67.2 M-$0.44	$87.7 M	-$88.7 M/-$0.58	$92.5 M
Fate	FATE	NA	NA	NA	NA	-$5.7 M/-$4.83	$19.0 M	-$6.0 M/+$8.70	$54.0 M
Fibrocell	FCSC	-$5.8 M/-$0.22	$26.1 M	-$12.9 M/-$0.24	$26.1 M	-$6.2 M/-$0.48	$20.8 M	-$5.8 M/-$0.09	$16.9 M
Harvard Apparatus	HART	NA	NA	NA	NA	NA	NA	-$2.6 M/-$0.34	$14.0 M
ImmunoCellular	IMUC	-$5.0 M/-$0.01	$24.1 M	-$150 K/$0.00	$25.4 M	-$3.8 M/-$0.07	$29.4 M	$-117 K/-$0.01	$27.6 M
Int'l. Stem Cell	ISCO	-$1.7 M/-$0.02	$1.9 M	$-2.2 M/-$0.02	$704.0 K	-$3.8 M/-$0.03	$1.8 M	-$-2.8 M/-$0.02	$2.3 M
Mesoblast	MBLTY	NA	NA	NA	NA	NA	NA	NA	NA
MiMedx	MDXG	$1.6 M/-$0.02	$5.7 M	-$757 K/-$0.01	$4.2 M	-$307 K/$0.00	$6.0 M	-$1.4 M/-$0.01	$44.1 M
NeoStem	NBS	-$8.8 M/-$0.53	$9.3 M	-$8.6 M/-$0.46	$14.7 M	-$9.1 M/-$0.45	$16.9 M	-$12.4M/-$0.47	$46.1 M
Northwest Bio	NWBO	-$/14.4 M/-$0.54	$373.0 K	-$11.6 M/-$0.40	$2.0 M	-$22.9 M/-$0.65	$7.4 M	-$16.89 M/-$2.00	$18.5 M
Organovo	ONVO	NA	$15.6 M	-$3.8 M/-$0.06	$12.8 M	-$10.4 M/-$0.14	$53.3 M	-$5.2 M/-$0.07	$49.8 M
OPXA	OPXA	-$4.2 M/-$0.58	$7.8 M	-$3.0 M/-$0.37	$5.0 M	-$346.2 K/-$0.39	$20.2 M	-$3.8 K/+0.04	$23.6 M
Osiris	OSIR	-$2,8 M/-$0.08	$1.3 M	-$3.8 M/-$0.11	$1.6 M	-$1.6 M/-$0.05	$1.8 M	+49.8 M/+$1.44	$2.4 M
Pluristem*	PSTI	-$5.7 M/-$0.08	$28.8 M	-$6.7 M/-$0.08	$9.3 M	-$4.8 M/-$0.01	$9.4 M	-$7.0 M/-$0.12	$5.1 M
StemCells	STEM	-$6.4 M/-$0.17	$7.2 M	-$5.9 M/-$0.18	$22.6 M	-$7.2 M/-$0.17	$21.0 M	-7.6 M/-$0.14	$30.6 M
Stemline	STML	-$5.5M/-$0.09	$30.7 M	-$5.5 M/-$0.47	$92.7 M	-$5.6 M /-$0.37	$87.7 M	-$7.7 M/-$0.61	$44.2 M
Tengion	TNGN	-$ 5.8 M/-$2.11	$7.5 M	-$ 11.9 M/-$3.73	$13.9 M	-$ 7.3 M/-$1.40	$22.5 M	+$6.0 M/$2.54	$21.5 M
Verastem	VSTM	-$9.0 M /-$0.44	$28.2 M	-$10.2 M/ -$0.50	$13.9 M	-$10.6 M /-$0.43	$22.6 M	-$11.3 M/-$0.45	$19.0 M
VistaGen*	VSTA	$131 K /-$0.16	$638 K	-$1.5 M /-$0.02	$90.0 K	+$186 K /-$0.04	$7.0 K	-$3.7 M/-$0.02	$21.0 K

* Jul - Jun Rptg.

Submitted by Henry McCusker on November 16, 2013 - 7:45pm

COMPANY	SYMBOL	REVENUE	DEBT	CASH	RECENT FINANCING	OP. EXP. Q1/14	FINANCE NEEDED?
Advanced Cell	ACTC	$39.5 K	$1.09 M	4.0 M		$7.7 M	Yes
Aastrom	ASTM	$11.00 K	$2.00 K	$8.84 M	$15 M (1/14)	$4.65 M	Yes
Athersys	ATHX	$707.0 K	$178.00 K	$44.98 M	$5 M (1/14)	$8.09 M
AxoGen	AXGN	$3.1 M	$26.26 M	$16.81 M		$5.42 M
Brainstrom	BCLI	NA	$0.00	$3.03 M	$3.7M (8/13)	$1.03 M	Yes
Bioheart	BHRT	$322.5 K	$5.65 M	$218.98 K		$943.5 K
Biolife Solutions	BLFS	$2.0 M	$0.00	$12.84 M	$15.4 (3/14)	$1.27 M
bluebird	BLUE	$6.3 M	$0.00	$192.5 M		$17.0 M
BioRestorative	BRTX	$375.00	$5.46 M	$110.36 K	$375.00 K (6/14)	$1.4 M	YES
BioTime	BTX	$1.0 M	$0.00	$6.64 M	$3.5 M (3/14)	$12.0 M	YES
Cytomedix	CMXI	$1.85 M	$2.18 M	$7.65 M	$35 M Debt Facility (4/14)	$5.0 M	YES
Neuralstem	NYSEMKT: CUR	$4.16 K	$7.04 M	$33.34 M	$19.65 M (1/14)	$5.18 M	Filed New Shelf
Cytori	CYTX	$1.0 M	$26.57 M	$12.80 M	$10.0 M (5/14)	$10.56 M	Yes
Dendreon	DNDN	$68.7 M	$609.58 M	$155.15 M		$91.86 M
Fibrocell	FCSC	$46 K	$0.00	$54.00 M	$11M (9/13)	$11.2 M
Harvard Apparatus	HART	$20.3 K	$0.00 M	$12.61 M		$3.0 M	Yes
Cellular Dynamics	ICEL	$2.39 M	$11.91 M	$53.7 M	$46 M (7/13)	$8.07 M
Immunocellular	IMUC	$1.65 M	$0.00	$25.45 M		$3.71M
Int'l Stem Cell	ISCO	$5.18 M	$0.00	$991.00 K		$1.64 M
Cesca Therap.	KOOL	$4.03 M	$0.00	$6.57 M	$6.67 (1/14)	$3.39 M
Mesoblast	MBLTY	$35.37 M	$0.00	$323.16 M		NA
MiMedx	MDXG	$43.53 M	$0.00	$43.0 M	$34 M (12/13)	$18.0 M
NeoStem	NBS	$4.0 M	$4.89 M	$41.36 M	$32.55 M (10/13)	$17.55 M
Northwest Bio	NWBO	$0.0	$1.17 M	$12.23 M	$32 M RDO $15 M initial sale	$23.68 M
Organovo	ONVO	$135.0 K	$18.0 K	$49.81 M	$46.6 M (8/13)	$4.7 M
Opexa	OPXA	$348.83 K	$0.00	$10.66 M	$8.054 M (12/13)	$3.66 M
Osiris	OSIR	$10.05 M	$45.00 K	$38.96 M		$8.45 M
Proteonomix	PROT	$26.00 K	$2.71 M	$2.40 M		$849.00 K / $2.21 M	Yes
Pluristem	PSTI	$285 K	$0.00	$60.12 M		$7.30 M/ $6.12 M
StemCells	STEM	$339.48 K	$15.96 M	$26.46 M	$18.6 M (10/13) $3.8 M (7/13)	$7.15 M
Stemline	STML	$71.00 K	$0.00	$24.20 M		$9.10 M
Tengion	TNGN	$0.00	$29.01 M	$15.37 M	$18.6 M (7/13)	$4.14 M	Yes
VistaGen	VSTA	$0.00 K	$6.39 M	$20.7 K		$1.44 M
Verastem	VSTM	$0.00	$0.00	$13.24 M	$50 M (7/13)	$13.13 M

Submitted by Henry McCusker on November 16, 2013 - 6:39pm

COMPANY	SYMBOL	TRIAL	FOCUS	PHASE
Advanced Cell	(ACTC)	RPE	Macular Degenration	P2
Advanced Cell	(ACTC)	RPE	Dry Age-Related Macular Degeneration	P2
Advanced Cell	(ACTC)	RPE	Stargardt's Macular Dystrophy (SMD)	P2
Aastrom	(ASTM)	ixCELL-DCM	Ischemic Dilated Cardiomyopathy	P2b
Athersys	(ATHX)	MultiStem®	Inflammatory Bowel Disease	P2
Athersys	(ATHX)	MultiStem®	HSC Transplant/GVHD	Orphan Status Granted
Athersys	(ATHX)	MultiStem®	Solid Organ Transplant	Trial authorized in Germany
Athersys	(ATHX)	MultiStem®	Diabetes	Preclinical
Athersys	(ATHX)	MultiStem®	Acute Myocardial Infarction	P2
Athersys	(ATHX)	MultiStem®	PVD/PAD/CLI	Preclinical
Athersys	(ATHX)	MultiStem®	Congestive Heart Failure	Preclinical
Athersys	(ATHX)	MultiStem®	Ischemic Stroke	P2
Athersys	(ATHX)	MultiStem®	Traumatic Brain Injury	Preclinical
Athersys	(ATHX)	MultiStem®	Multiple Sclerosis	Preclinical
Athersys	(ATHX)	MultiStem®	Spinal Cord Injury	Preclinical
Bioheart	(ZOTC: BHRT)	ANGEL	Agiogenesis (Blood Cells/Healing)	P1
Bioheart	(BHRT)	MARVEL	Cardiac Disease/MI	P2/3
Bioheart	(BHRT)	MIRROR	Cardiac Disease/MI	P3
Bioheart	(BHRT)	MYOHEART	Cardiac Disease/MI	P1
Bioheart	(BHRT)	REGEN	Cardiac Disease/MI	P1
Bioheart	(BHRT)	Drug: MyoCell	Congestive Heart Failure	P2
Bioheart	(BHRT)	Procedure: Hypothermosol	Congestive Heart Failure	P3
Biorestorative	(BRTX)	NA	NA	NA
BioLife Solutions	(BLFS)	NA	Tools company supplying	NA
Dendreon	(DNDN)	Active Cellular Immunotherapy	Ovarian Cancer Expressing HER2/NEU	P1
Dendreon	(DNDN)	Active Cellular Immunotherapy	Colorectal Cancer Expressing HER2/NEU	P1
FibroCell	(NTSE MKT: FCSC)	Isolagen Therapy™	Nasolabial Fold Wrikles	P3 Completed.
FibroCell	(FCSC)	Isolagen Therapy™	Acne Scarring w/Therapy	P2
FibroCell	(FCSC)	Isolagen Therapy™	Acne Scarring w/Placebo	P3 Completed.
FibroCell	(FCSC)	Isolagen Therapy™	Restrictive Burn Scars	P2
FibroCell	(FCSC)	Isolagen Therapy™	Interdental Papillary Insufficiency	P2
International Stem	(OTC: ISCO)	Dopaminergic Neurons	Parkinson's Disease	Preclinical
International Stem	(OTC: ISCO)	Hepatocytes	Liver Disease	Preclinical
International Stem	(OTC: ISCO)	Corneal Tissue	Blindness	Preclinical
Harvard Appartus	(HART)
Immunocellular	(IMUC)	ICT-121	Recurrent Glioblastoma	P1
Immunocellular	(IMUC)	ICT-107	Vaccine for Glioblatoma	P2
Immunocellular	(IMUC)	ICT-140	Ovarian Cancer	Preclinical
Mesoblast ADR	(US OTC: MBLTY)	Allogenic Meneschymal	Damaged Intervertebral Discs	P2
Mesoblast	(MBLTY)	Immunologic Inflammatory	Rheumatoid Arthritis	P2
Mesoblast	(MBLTY)	Immunologic Inflammatory	Asthma Pulmonary Fibrosis	Preclinical
Mesoblast	(MBLTY)	Immunologic Inflammatory	Type 2 Diabetes	P2
Mesoblast	(MBLTY)	Immunologic Inflammatory	Diabetic Complications (Kidney)	P2
Mesoblast	(MBLTY)	Spine Disease	Spinal Fusion	P2
Mesoblast	(MBLTY)	Spine Disease	Intervertebral Disc Repair	P2
Mesoblast	(MBLTY)	Cardiovascular	Congestive Heart Failure	P2
Mesoblast	(MBLTY)	Cardiovascular	Acute Myocardial Infarction	P2
Mesoblast	(MBLTY)	Cardiovascular	Chronic Angina	Preclinical
Mesoblast	(MBLTY)	Neurologic	Parkinson's Stroke	P1
Mesoblast	(MBLTY)	Eye Disease	Wet Macular Degeneration	P2
Mesoblast	(MBLTY)	Orthopedic Disease	Bone Marrow Transplantation	P3
Mesoblast	(MBLTY)	Prochymal®	Steroid Refractory Acute GvHD	P3
Mesoblast	(MBLTY)	Prochymal®	Newly Diagnosed Acute GVHD	P3
Mesoblast	(MBLTY)	Prochymal®	Pediatric Expanded Access Program	Enrolling
Mesoblast	(MBLTY)	Prochymal®	Crohn's Disease	P3/Accepting Patients
Mesoblast	(MBLTY)	Prochymal®	Type 1 Diabetes	P2
Mesoblast	(MBLTY)	Prochymal®	Cardiac	P2
Medistem	(MEDS)	ERC-123	Critical Limb Ischemia	P1
Medistem	(MEDS)	ERC-123	Congestive Heart Failure	P2
MiMidxg	(MDXG)	Amneotic Membrane	Diabetic Foot Ulcers	Comparative Study v/SOC
NeoStem	(NBS)	AMR-001	ST Segment Elevation Myocardial Infarction	P2
Neuralstem	(CUR)	NSI-566	Cell Therapy Treatments:
Neuralstem	(CUR)	NSI-566	Amotrophic Lateral Sclerosis (ALS)	P2
Neuralstem	(CUR)	NSI-566	Ischemic Stroke	P1/P2
Neuralstem	(CUR)	NSI-566	Spinal Cord Injury	P1
Neuralstem	(CUR)	NSI-566	Multiple Sclerosis	Preclinical
Neuralstem	(CUR)	NSI-566	Optic Neuritis	Preclinical
Neuralstem	(CUR)	NSI-566	Alzheimer's Disease	Preclinical
Neuralstem	(CUR)	NSI-566	Traumatic Brain Injury	Preclinical
Neuralstem	(CUR)	NSI-566	Peripheral Nerve Injury	Preclinical
Neuralstem	(CUR)	NSI-566	Lysomal Diseases	Preclinical
Neuralstem	(CUR)	NSI-566	Huntington's Disease	Preclinical
Neuralstem	(CUR)	NSI-566	Cerebral Palsy	Preclinical
Neuralstem	(CUR)	NSI-566	Ischemic Spastic Paraplegia	Preclinical
Neuralstem	(CUR)	NS-189	Drug Therapies:
Neuralstem	(CUR)	NS-189	Major Depressive Disorder	P1b
Neuralstem	(CUR)	NS-189	Alzheimer's Disease	Preclinical
Neuralstem	(CUR)	NS-189	Diabetes Cognitive Complication	Preclinical
Neuralstem	(CUR)	NS-189	Stroke	Preclinical
Neuralstem	(CUR)	NS-189	Traumatic Brain Injury	Preclinical
Neuralstem	(CUR)	NS-189	Post-Traumatic Stress Disorder	Preclinical
Neuralstem	(CUR)	NS-189	Neurodegeneration	Preclinical
Neuralstem	(CUR)	NS-189	Anti-Aging	Preclinical
Northwest Bio	(NWBO)	DCVax®	Brain Cancers	P2
Northwest Bio	(NWBO)	DCVax®	Prostate Cancer	P3
Northwest Bio	(NWBO)	DCVax®	Lung Cancer	P1
Northwest Bio	(NWBO)	DCVax®	Ovarian Cancer	P1
Northwest Bio	(NWBO)	DCVax®	Liver Cancer	P1
Northwest Bio	(NWBO)	DCVax®	Head and Neck Cancers	P1
Northwest Bio	(NWBO)	CXCR4	Antibody Drugs	P1
Opexa	(OPXA)	Abili-T	Secondary Progressive Multiple Sclerosis	P2
Opexa	(OPXA)	Tcelna®	Secondary Progressive Multiple Sclerosis	P2b FAST TRACK
Organovo	(ONVO)	NA	3D Human Tissue for Medical Research	Preclinical
Pluristem	(PSTI)	Placental eXpanded (PLX)	Peripheral Artery Disease (PAD)	P2/3
Pluristem	(PSTI)	PLX	Skeletal Injuries	Preclinical
Pluristem	(PSTI)	PLX	Adjuvant for UCB Transplantation	Preclinical
Proteonomix	(PROT)	GSF and Mozobil	End Stage Liver Disease	Phase 1
Reneuron	(RENE.L)	PISCES	Stroke	P1
StemCells	(STEM)	HuCNS-SC®	Dry Age-Related Macular Degeneration	P1/2
StemCells	(STEM)	HuCNS-SC®	Spinal Cord Injury	P1/2
StemCells	(STEM)	HuCNS-SC®	Pelizaeus-Merzbacher Disease (PMD)	P1
Stemline	(STML)	SL-401	BPDCN	P1/2
Stemline	(STML)	SL-401	Other Rare 3R+ Cancers	P1/2
Stemline	(STML)	SL-401	Acute Myeloid Leukemia (AML)	P1/2
Stemline	(STML)	SL-401	Multiple Myeloma	P1/2
Stemline	(STML)	SL-401	High Risk MDS	P1/2
Stemline	(STML)	SL-401	Other Hematologic Cancers	P1/2
Stemline	(STML)	SL-701	Pediatric Malignant Glioma	P1/2
Stemline	(STML)	SL-701	Adult High-Grade Glioma	P1/2
Tengion	(TNGN)	Neo-Urinary Conduit™	Bladder Cancer	P1
Tengion	(TNGN)	Neo-Kidney-Augment™	Chronic Kidney Disease	P1
Thermogenesis	(KOOL)	Bone Marrow Delivery	Critical Limb Ischemia	P1b
VistaGen	(VSTA)	AV-101 IND	Neuropathic Pain	P2
Verastem	(VSTM)	Defactinib (VS-6063)	Mesothelioma	P2
Verastem	(VSTM)	VS-6063 w/Paclitaxel	Ovarian Cancer	P1/1b
Verastem	(VSTM)	VS-4718	Non Hematologic Cancers	P1 - Recruiting
Verastem	(VSTM)	VS-6063	Non Small Cell Lung Cancer/Lung Cancer	P2 - Recruiting
Verastem	(VSTM)	VS-6063	JAPANESE Subjects w/Non Hematologic	P1 - Recruiting
Verastem	(VSTM)	VS-6063	Malignancies

Submitted by Henry McCusker on February 23, 2014 - 3:20pm

COMPANY	YEAR	SALARY	BONUS	STOCK AWARDS ($)	OPTIONS ($)	NON EQUITY INCENTIVE PLAN ($)	ALL OTHER COMP	TOTAL ($)	52 WEEK RANGE	CURRENT MARKET CAP
ADVANCED CELL (ACTC) Gary Rabin CEO	2013	$551.2 K	$0.00	$0.00	$0.00	$0.00	$0.00	$551.2 K	$0.05 - $0.10	$164.8 M
	2012	$525.0 K	$0.00	$0.00	$0.00	$315 K	$0.00	$840 K
	2011	$490.0 K	$649.3 K	$2.5 M	$3.45 M	$0.00	$0.00	$7.14 M
ADVANCED CELL (ACTC) Robert Lanza CSO	2013	$485.1 K	$101.1 K	$79.7 K	$69.9 K	$0.00	$0.00	$735.7 K
	2012	$462.0 K	$0.00	$0.00	$0.00	$138.6 K	$0.00	$184.6 K
	2011	$407.5 K	$255.0 K	$1.7 M	$2.5 M	$0.00	$0.00	$4.8 M
ADVANCED CELL (ACTC) Edward Myles Interim CFO	2013	$175.2 K	$135.5 K	$0.00	$1.0 M	$0.00	$0.00	$1.4 M
AASTROM (ASTM) Dominic Colangelo CEO	2013	$358.4 K	$0.00	$0.00	$937.8 K	$89.5 K	$59.3 K	$1.4 M	$3.14 - $86.00	$24.53 M
AASTROM (ASTM) Daniel Orlando COO, Interim CEO	2013	$285.0 K	$35 K	$0.00	$0.00	$45.6 K	$45.6 K	$412.2 K
AASTROM (ASTM) Daniel Orlando COO, Interim CEO	2012	$99.9 K	$0.00	$0.00	$485.4 K	$0.00	$0.5 K	$585.8 K
AASTROM (ASTM) Ronnda Bartel CSO	2013	$260.0 K	$0.00	$0.00	$0.00	$0.00	$28.9 K	$288.9 K
	2012	$253.0 K	$0.00	$0.00	$209.1 K	$0.00	$9.6 K	$471.7 K
	2011	$243.3 K	$14.8 K	$0.00	$235.9 K	$85.1 K	$7.1 K	$586.2 K
AASTROM (ASTM) Sharon Watling V.P. Dev.	2013	$79.8 K	$0.00	$0.00	$0.00	$0.00	$185.3 K	$265.1 K
	2012	$245.0 K	NA	$0.00	$199.0 K	$0.00	$10.4 K	$454.4 K
	2011	$210.6 K	NA	$0.00	$333.1 K	$70.0 K	$9.7 K	$623.4 K
AASTROM (ASTM) Brian Gibson V.P. Fin	2013	$110.0 K	$0.00	$0.00	$0.00	$0.00	$32.4 K	$265.1 K
	2012	$165.0 K	$0.00	$0.00	$319.3 K	$0.00	$21.1 K	$505.4 K
	2011	$123.3 K	$0.00	$0.00	$105.5 K	$40.0 K	$6.4 K	$275.2 K
AASTROM (ASTM) Michael Ellison CAO	2013	$113.5 K	$0.00	$0.00	$0.00	$17.5 K	$4.8 K	$135.8 K
ATHERSYS (ATHX) Gil Van Bokkelen CEO	2013	$450.0 K	$118.0 K	$1.2 M	$264.6 K	$0.00	$12.6 K	$2.03 M	$1.08 - $4.33	$118.3 M
	2012	$430.0 K	$107.5 K	$0.00	$0.00	$0.00	$12.6 K	$550.1 K
	2011	$404.5 K	$40 K	$0.00	$0.00	$0.00	$12.6 K	$457.1 K
ATHERSYS (ATHX) Laura Campbell V.P. Fin.	2013	$239.3 K	$42.0 K	$632.0 K	$85.8 K	$0.00	$5.1 K	$1.0 M
	2012	$231.5 K	$40.5 K	$0.00	$0.00	$0.00	$5.1 K	$277.1 K
	2011	$225.3 K	$15.3 K	$0.00	$0.00	$0.00	$5.1 K	$245.7 K
ATHERSYS (ATHX) William Lehmann Pres.	2013	$371.4 K	$84.0 K	$980.9 K	$164.5 K	$0.00	$4.6 K	$1.6 M
	2012	$358.8 K	$77.0 K	$0.00	$0.00	$0.00	$4.6 K	$440.4 K
	2011	$346.7 K	$27.0 K	$0.00	$0.00	$0.00	$4.6 K	$378.3 K
ATHERSYS (ATHX) John Harrington CSO	2013	$369.4 K	$83.5 K	$975.6 K	$143.0 K	$0.00	$4.4 K	$1.6 M
	2012	$357.1 K	$77.8 K	$0.00	$0.00	$0.00	$4.3 K	$439.2 K
	2011	$346.7 K	$27.0 K	$0.00	$0.00	$0.00	$4.3 K	$378.0 K
ATHERSYS (ATHX) Robert Deans EVP	2013	$318.0 K	$65.0 K	$839.9 K	$114.4 K	$0.00	$5.6 K	$1.3 M
	2012	$307.5 K	$62.3 K	$0.00	$0.00	$0.00	$5.6 K	$375.4 K
	2011	$393.8 K	$24.3 K	$0.00	$0.00	$0.00	$5.6 K	$423.7 K
AXOGEN (AXGN) Karen Zaderej CEO	2013	$299.6 K	$14.9 K	$0.00	$0.00	$0.00	$6.1 K	$322.60	$2.42 - $5.20	$45.6 M
AXOGEN (AXGN) Karen Zaderej CEO	2012	$291.2 K	$11.6 K	$0.00	$0.00	$0.00	$0.00	$310.7 K
AXOGEN (AXGN) Gregory Freitag Former CEO	2013	$240.0 K	$11.6 K	$0.00	$0.00	$0.00	$7.6 K	$259.3 K
AXOGEN (AXGN) Gregory Freitag Former CEO	2012	$204.1 K	$8.2 K	$0.00	$0.00	$0.00	$5.6 K	$217.8 K
AXOGEN (AXGN) Shawn McCarrey SVP/SALES	2013	$161.5 K	$153.0 K	$0.00	$144.5 K	$0.00	$11.9 K	$471.1 K
AXOGEN (AXGN) Jill Schiaparelli SVP/MKTG.	2013	$220.1 K	$11.0 K	$0.00	$0.00	$0.00	$6.9 K	$238.0 K
AXOGEN (AXGN) Jill Schiaparelli SVP/MKTG.	2012	$173.7 K	$6.2 K	$0.00	$208.7 K	$0.00	$5.4 K	$394.0 K
BIOHEART (BHRT) Mike Tomas CEO	2013	$391.7 K	$375.0 K	$0.00	$170.1 K	$0.00	$0.00	$936.8 K	$0.01 - $0.08	$12.6 M
	2012	$247.5 K	$0.00	$0.00	$100.0 K	$0.00	$0.00	$347.5 K
	2011	$230.5 K	$0.00	$0.00	$40.0 K	$0.00	$0.00	$270.5 K
BIOHEART (BHRT) Kristin Comella CSO	2013	$159.1 K	$125.0 K	$0.00	$81.9 K	$0.00	$0.00	$369.1 K
	2012	$105.6 K	$0.00	$0.00	$15.0 K	$0.00	$0.00	$120.6 K
	2011	$106.2 K	$0.00	$0.00	$20.0 K	$0.00	$0.00	$126.2 K
BIOLIFE SOLUTIONS (BLFS) Michael Rice CEO	2013	$300.0 K	$150.0 K	$0.00	$0.00	$0.00	$0.00	$450.0 K	$1.85 -$23.94	$13.8 M
	2012	$285.0 K	$150.0 K	$0.00	$0.00	$0.00	$24.1 K	$459.1 K
	2011	$270.0 K	$0.00	$0.00	$161.2 K	$0.00	$0.00	$431.2 K
BIOLIFE SOLUTIONS (BLFS) Daphne Taylor CFO	2013	$194.0 K	$19.4 K	$0.00	$0.00	$0.00	$0.00	$213.8 K
	2012	$160.0 K	$18.0 K	$0.00	$19.7 K	$0.00	$0.00	$197.7 K
	2011	$102.0 K	$0.00	$0.00	$44.1 K	$0.00	$0.00	$146.2 K
BIOLIFE SOLUTIONS (BLFS) Aby Matthew CTO	2013	$218.0 K	$21.8 K	$0.00	$0.00	$0.00	$0.00	$239.8 K
BIOLIFE SOLUTIONS (BLFS) Aby Matthew CTO	2012	$177.8 K	$20.0 K	$0.00	$19.7 K	$0.00	$0.00	$217.5 K
BIORESTORATIVE (BRTX) Mark Weinreb CEO	2013	$360.0 K	$0.00	$0.00	$50.5 K	$0.00	$14.4 K	$425.0 K	$0.28 - $0.19	$8.9 M
	2012	$509.0 K	$324.5 K	$0.00	$696.0 K	$0.00	$231.5 K	$1.7 M
	2011	$390 K	$195.0 K	$123.9 K	$0.00	$0.00	$87.9 K	$796.8 K
BIORESTORATIVE (BRTX) Francisco Silva VP	2013	$230.0 K	$0.00	$0.00	$20.2 K	$0.00	$0.00	$250.2 K
	2012	$176.1 K	$0.00	$0.00	$115.2 K	$0.00	$0.00	$294.4 K
	2011	$110.7 K	$30.0 K	$0.00	$41.6 K	$0.00	$0.00	$182.3 K
BIORESTORATIVE (BRTX) Mandy Clyde Pres. Ops.	2013	$118.0 K	$0.00	$0.00	$16.18 K	$0.00	$0.00	$134.2 K
BIORESTORATIVE (BRTX) Mandy Clyde Pres. Ops.	2012	$100.0 K	$0.00	$0.00	$49.9 K	$0.00	$0.00	$149.9 K
BIOTIME (BTX) Michael West CEO	2013	$680.3 K	$65.0 K	$0.00	$851.6 K	$0.00	$37.8 K	$1.6 M	$2.21 - $4.82	$142.9 M
	2012	$660.5 K	$110.0 K	$0.00	$0.00	$0.00	$24.5 K	$785.0 K
	2011	$560.5 K	$266.0 K	$0.00	$10.6 K	$0.00	$19.0 K	$856.2 K
BIOTIME (BTX) Robert Peabody SVP	2013	$405.1 K	$145.0 K	$0.00	$521.5 K	$0.00	$12.0 K	$1.0 M
	2012	$386.9 K	$45 K	$0.00	$0.00	$0.00	$12.5 K	$444.4 K
	2011	$336.9 K	$156.0 K	$0.00	$5.3 K	$0.00	$12.4 K	$510.6 K
BIOTIME (BTX) Peter Garcia CFO	2013	$154.7 K	$0.00	$0.00	$520.8 K	$0.00	$12.8 K	$688.2 K
	2012	$324.0 K	$100.0 K	$0.00	$0.00	$0.00	$12.5 K	$436.5 K
	2011	$81.0 K	$6.0 K	$0.00	$703.2 K	$0.00	$3.4 K	$793.6 K
BIOTIME (BTX) Leslie Stoltz EVP	2013	$104.2 K	$0.00	$0.00	$591.3 K	$0.00	$0.00	$695.5 K
BIOTIME (BTX) William Tew CCO	2013	$285.0 K	$30.0 K	$0.00	$348.3 K	$0.00	$12.8 K	$671.0 K
	2012	$237.5 K	$20.0 K	$0.00	$0.00	$0.00	$11.1 K	$268.6 K
	2011	$145.0 K	$26.0 K	$0.00	$177.0 K	$0.00	$7.3 K	$355.3 K
BLUEBIRD (BLUE) Nick Leschly CEO	2013	$392.5 K	$0.00	$0.00	$1.8 M	$234.0 K	$0.00	$2.5 M	$17.03 - $36.25	$659.4 M
BLUEBIRD (BLUE) Nick Leschly CEO	2012	$346.0 K	$0.00	$0.00	$130.7 K	$124.2 K	$0.00	$601.0 K
BLUEBIRD (BLUE) Jeffrey Walsh COO	2013	$321.7 K	$0.00	$0.00	$395.8 K	$147.8 K	$0.00	$865.3 K
BLUEBIRD (BLUE) Jeffrey Walsh COO	2012	$300.7 K	$0.00	$0.00	$0.00	$108.0 K	$0.00	$408.7 K
BLUEBIRD (BLUE) Michael Finer CSO	2013	$307.2 K	$0.00		$640.2 K	$126.4 K	$0.00	$1.1 M
BRAINSTORM (BCLI) Alon Natonson Former CEO	2013	$117.0 K	$0.00	$0.00	$0.00	$0.00	$94.0 K	$211.0 K	$0.10 - $0.37	$44.8 M
BRAINSTORM (BCLI) Adrian Harel DIR RES/FMR CEO	2013	$130.0 K	$11.0 K	$0.00	$0.00	$0.00	$70.0 K	$211.0 K
	2012	$121.4 K	$60.0 K	$0.00	$16.0 K	$0.00	$71.2 K	$268.7 K
	2011	$117.0 K	$0.00	$0.00	$203.0 K	$0.00	$65.0 K	$385.0 K
BRAINSTORM (BCLI) Liat Sossover CFO	2013	$106.0 K	$0.00	$0.00	$16.0 K	$0.00	$65.0 K	$187.0 K
	2012	$99.3 K	$20.0 K	$0.00	$13.7 K	$0.00	$56.0 K	$189.0 K
	2011	$98.0 K	$0.00	$0.00	$0.00	$0.00	$46.0 K	$144.0 K
CAPRICOR (CAPR) Linda Marbán CEO	2013	$232.4 K	$0.00	$0.00	$108.0 K	$0.00	$0.00	$340.3 K	$1.50 - $17.15	$63.1 M
CAPRICOR (CAPR) Linda Marbán CEO	2012	$190.3 K	$0.00	$0.00	$0.00	$0.00	$0.00	$190.3 K
CAPRICOR (CAPR) Karen Krasney EVP/Counsel	2013	$189.4 K	$0.00	$0.00	$0.00	$0.00	$1.0 K	$190.4 K
CAPRICOR (CAPR) Karen Krasney EVP/Counsel	2012	$130.0 K	$0.00	$0.00	$54.7 K	$0.00	$1.0 K	$185.7 K
CAPRICOR (CAPR) Anthony Davies CTO	2013	$213.1 K	$0.00	$0.00	$49.3 K	$0.00	$40.6 K	$302.9 K
CAPRICOR (CAPR) Darlene Horton Former CEO	2013	$1.0 K	$239.3 K	$0.00	$0.00	$0.00	$0.00	$240.3 K
CAPRICOR (CAPR) Darlene Horton Former CEO	2012	$81.4 K	$0.00	$0.00	$0.00	$0.00	$0.00	$81.4 K
CESCA (KOOL) (THERMOGENESIS) Matthew Plavan CEO	2013	$315.0 K	$0.00	$0.00	$88.0 K	$0.00	$8.0 K	$403.0 K	$0.71 -$3.24	$45.0 M
	2012	$315.0 K	$0.00	$149.0 K	$0.00	$0.00	$0.00	$464.0 K
	2011	$301.0 K	$89.0 K	$68.0 K	$92.0 K	$0.00	$0.00	$550.0 K
CESCA (KOOL) (THERMOGENESIS) Hal Baker VP/OPS	2013	$263.0 K	$99.0 K	$0.00	$0.00	$0.00	$8.0 K	$370.0 K
	2012	$262.0 K	$85.0 K	$99.0 K	$0.00	$0.00	$9.0 K	$455.0 K
	2011	$250.0 K	$178.0 K	$0.00	$69.0 K	$0.00	$8.0 K	$505.0 K
CESCA (KOOL) (THERMOGENESIS) Kevin Cooksy VP/DEV	2013	$240.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$240.0 K
CESCA (KOOL) (THERMOGENESIS) Kevin Cooksy VP/DEV	2012	$193.0 K	$4.0 K	$82.0 K	$0.00	$0.00	$0.00	$279.0 K
CESCA (KOOL) (THERMOGENESIS) Ken Pappa VP/MANUF	2013	$245.0 K	$25.0 K	$0.00	$0.00	$0.00	$0.00	$270.0 K
	2012	$239.0 K	$0.00	$99.0 K	$0.00	$0.00	$0.00	$338.0 K
	2011	$215.0 K	$0.00	$0.00	$35.0 K	$0.00	$0.00	$250.0 K
CYTORI (CYTX) Christopher Calhoun Former CEO	2013	$467.9 K	$0.00	$635.3 K	$0.00	$82.5 K	$0.00	$1.2 M	$2.00 - $3.93	$172.8 M
	2012	$467.9 M	$0.00	$293.2 K	$483.9 K	$109.9 K	$0.00	$1.3 M
	2011	$456.5 K	$0.00	$292.4 K	$252.80	$140.30	$10.2 K	$1.1 M
CYTORI (CYTX) Marc Hendrick CEO	2013	$406.6 K	$0.00	$0.00	$465.9 K	$89.1 K	$0.00	$961.6 K
	2012	$406.6 K	$0.00	$212.7 K	$241.9 K	$76.4 K	$0.00	$937.8 K
	2011	$396.7 K	$0.00	$214.4 K	$185.4 K	$97.5 K	$0.00	$894.2 K
CYTORI (CYTX) Mark Saad CFO	2013	$389.9 K	$0.00	$0.00	$381.1 K	$35.6 K	$0.00	$806.7 K
	2012	$389.9 K	$0.00	$184.0 K	$84.1 K	$64.1 K	$0.00	$722.2 K
	2011	$380.4 K	$0.00	$194.9 K	$160.1 K	$81.8 K	$0.00	$825.8 K
	2010	$366.4 K	$0.00	$0.00	$407.3 K	$109.9 K	$0.00	$883.7 K
CYTORI (CYTX) Steven Kesten Pres. & CEO	2013	$333.3 K	$0.00	$0.00	$271.1 K	$38.9 K	$143.4 K	$786.8 K
CYTORI (CYTX) Clyde Shores EVP	2013	$329.4 K	$0.00	$0.00	$254.1 K	$25.2 K	$35.0 K	$641.8 K
CYTORI (CYTX) Clyde Shors	2012	$329.4 K	$0.00	$178.2 K	$84.1 K	$65.2 K	$44.4 K	$701.5 K
DENDREON (DNDN) John Johnson CEO	2013	$800.0 K	$0.00	$4.3 M	$0.00	$456.0 K	$7.7 K	$5.6 M	$1.81-$5.38	$369.2 M
DENDREON (DNDN) John Johnson CEO	2012	$736.4 K	$0.00	$4.7 M	$4.7 M	$912.0 K	$825.00	$11.2 M
DENDREON (DNDN) Gregory Schiffman CFO	2013	$450.0 K	$0.00	$1.1 M	$0.00	$128.3 K	907.0 K	$2.6 M
	2012	$437.0 K	$0.00	$1.1 M	NA	$118.0 K	$8.0 K	$1.6 M
	2011	$437.0 K	$0.00	$750.0 K	NA	$109.2 K	$6.9 K	$1.3 M
DENDREON (DNDN) Gregory Cox INTERIM CFO	2013	$354.1 K	$524.8 K	$0.00	$0.00	$128.3 K	$6.3 K	$1.0 M
DENDREON (DNDN) Mark Frohlich CMO	2013	$464.0 K	$1.09 M	$0.00	$0.00	$128.3 K	$906.6 K	$2.6 M
	2012	$450.0 K	$0.00	$2.4 K	$0.00	$122.0 K	$7.2 K	$3.0 M
	2011	$446.6 K	$0.00	$750.0 K	$0.00	$112.5 K	$7.3 K	$1.3 M
	2010	$360.0 K	$0.00	$642.6 K	$878.7 K	$171.7 K	$7.7 K	$2.0 M
DENDREON (DNDN) Christine Mikail COUNSEL	2013	$412.0 K	$0.00	$1.1 M	$0.00	$117.4 K	$6.2 K	$1.6 M
DENDREON (DNDN) Christine Mikail COUNSEL	2012	$334.8 K	$0.00	$650.6 K	$885.3 K	$475.5 K	$5.0 K	$2.3 M
DENDREON (DNDN) Joseph Depinto EVP/OPS	2013	$402.0 K	$0.00	$1.09 M	$0.00	$114.6 K	$9.6 K	$1.6 M
	2011	$400.0 K	$0.00	$750.0 K	$0.00	$100.0 K	$120.6 K	$1.3 M
	2010	$246.8 K	$0.00	$1.8 K	$2.5 M	$170.0 K	$128.8 K	$4.9 M
DENDREON (DNDN) John Maslowski VP OPS.	2012	$188.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$188.0 K
DENDREON (DNDN) John Maslowski VP OPS.	2011	$164.9 K	$20.0 K	$0.00	$137.2 K	$0.00	$0.00	$322.1 K
DENDREON (DNDN) Elizabeth Browning EVP MKT.	2012	$250.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$250.0 K
FATE THERAPEUTICS (FATE) Christian Weyer CEO	2013	$350.0 K	$0.00	$0.00	$0.00	$153.1 K	$0.00	$503.1 K	$4.30 - $13.55	$135.1 M
FATE THERAPEUTICS (FATE) Christian Weyer CEO	2012	$74.0 K	$0.00	$0.00	$677.5 K	$0.00	$0.00	$751.5 K
FATE THERAPEUTICS (FATE) J. Scott Wolchko CFO/COO	2013	$256.0 K	$0.00	$0.00	$145.2 K	$64.5 K	$0.00	$465.7 K
FATE THERAPEUTICS (FATE) J. Scott Wolchko CFO/COO	2012	$241.0 K	$0.00	$0.00	$96.1 K	$0.00	$0.00	$337.1 K
FATE THERAPEUTICS (FATE) Pratik Multani CMO	2013	318.00	$0.00	$0.00	$145.2 K	$66.8 K	$0.00	$530.0 K
FATE THERAPEUTICS (FATE) Pratik Multani CMO	2012	$313.0 K	$0.00	$102.3 K	$0.00	$0.00	$0.00	$415.3 K
HARVARD APPARATUS (HART) David Green CEO	2013	$84.1 K	$0.00	$0.00	$2.2 M	$0.00	$4.3 K	$2.3 M	$2.00 - $11.89	$54.8 M
HARVARD APPARATUS (HART) Thomas McNaughton CFO	2013	$51.5 K	$0.00	$0.00	$560.0 K	$0.00	$2.1 K	$613.7 K
IMMUNOCELLULAR (IMUC) Andrew Gegnos Pres. CEO	2012	$33.3 K	$0.00	$0.00	$791.4 K	$0.00	$0.00	$824.7 K	$0.65 - $4.00	$80.7 M
IMMUNOCELLULAR (IMUC) Andrew Gegnos Pres. CEO	2011	NA	$0.00	$0.00	$0.00	$0.00	$0.00	NA
IMMUNOCELLULAR (IMUC) John Yu Pres. CEO	2012	$67.7 K	$40.0 K	$0.00	$70.5 K	$0.00	$108.9 K	$287.1 K
IMMUNOCELLULAR (IMUC) Manish Singh Pres. CEO	2012	$202.7 K	$0.00	$0.00	$0.00	$0.00	$0.00	$202.7 K
IMMUNOCELLULAR (IMUC) Manish Singh Pres. CEO	2011	$313.1 K	$50.0 K	$0.00	$393.5 K	$0.00	$0.00	$756.6 K
IMMUNOCELLULAR (IMUC) David Factor CFO	2012	$116.4 K	$20.0 K	$0.00	$10.3 K	$0.00	$0.00	$146.7 K
IMMUNOCELLULAR (IMUC) David Factor CFO	2011	$62.0 K	$0.00	$0.00	$52.1 K	$0.00	$0.00	$114.1 K
IMMUNOCELLULAR (IMUC) James Bender VP/Prod. Dev.	2012	$186.9 K	$34.1 K	$0.00	$145.4 K	$0.00	$0.00	$366.4 K
IMMUNOCELLULAR (IMUC) James Bender VP/Prod. Dev.	2011	$174.5 K	$20.0 K	$0.00	$134.8 K	$0.00	$0.00	$329.3 K
INT'L STEM (ISCO) Andrew Semechkin Chair/CEO	2013	$258.5 K	$0.00	$0.00	$23.0 K	$0.00	$0.00	$281.5 K	$0.13 - $0.30	$23.8 M
	2012	$255.0 K	$0.00	$0.00	$176.8 K	$0.00	$0.00	$431.8 K
	2011	$255.3 K	$0.00	$0.00	$2.8 M	$0.00	$0.00	$3.0 M
INT'L STEM (ISCO) John Craw	2013	$220.0 K	$0.00	$0.00	$17.3 K	$0.00	$0.00	$237.3 K
INT'L STEM (ISCO) John Craw	2012	$215.7 K	$0.00	$0.00	$51.6 K	$0.00	$0.00	$267.4 K
INT'L STEM (ISCO) Ruslan Semechkin CSO	2013	$182.0 K	$0.00	$0.00	$16.1 K	$0.00	$0.00	$198.2 K
	2012	$176.5 K	$0.00	$0.00	$59.3 K	$0.00	$0.00	$235.8 K
	2011	$176.5 K	$0.00	$0.00	$581.6 K	$0.00	$0.00	$758.2 K
MESOBLAST (MBLTY) NA (AUSTRALIA) NO FINANCIALS W/SEC SOURCE: BLOOMBERG Silviu Itescu CEO	2013	1.7 AUD							$21.39 - $31.60	$1.39 B
MIMEDX (MDXG) Parker Petit CEO	2013	$456.2 K	$0.00	$548.3 K	$954.0 K	$292.5 K	$0.00	$2.3 M	$1.81 - $8.80	$569.8 M
	2012	$354.3 K	$0.00	$0.00	$706.7 K	$0.00	$0.00	$1.0 M
	2011	$325.0 K	$0.00	$0.00	$696.5 K	$0.00	$0.00	$1.0 M
MIMEDX (MDXG) William Taylor COO	2013	$385.6 K	$0.00	$377.6 K	$649.0 K	$240.7 K	$0.00	$1.7 M
	2012	$343.8 K	$0.00	$0.00	$530.0 K	$0.00	$0.00	$873.8 K
	2011	$300.0 K	$0.00	$0.00	$352.8 K	$0.00	$0.00	$652.8 K
MIMEDX (MDXG) Roberta McCraw Counsel	2013	$240.0 K	$0.00	$71.0 K	$156.4 K	$106.3 K	$0.00	$573.8 K
MIMEDX (MDXG) Michael Senken CFO	2013	$268.3 K	$0.00	$172.0 K	$278.0 K	$121.9 K	$0.00	$840.3 K
	2012	$236.5 K	$0.00	$0.00	$160.2 K	$0.00	$0.00	$396.7 K
	2011	$198.2 K	$0.00	$0.00	$213.9 K	$0.00	$0.00	$412.2 K
NEOSTEM (NBS) Robin Smith CEO	2013	$495.0 K	$450.0 K	$0.00	$249.7 K	$0.00	$40.8 K	$1.2 M	$4.56 - $9.89	$173.6 M
	2012	$412.6 K	$363.0 K	$183.8 K	$638.9 K	$0.00	$44.9 K	$1.6 M
	2011	$375.1 K	$330.0 K	$0.00	$2.9 M	$0.00	$30.4 K	$3.6 M
NEOSTEM (NBS) Robert Preti CSO	2013	$349.2 K	$145.0 K	$0.00	$143.2 K	$0.00	$0.00	$637.5 M
	2012	$309.8 K	$0.00	$0.00	$97.5 K	$0.00	$0.00	$407.4 K
	2011	$300.8 K	$0.00	$0.00	$439.0 K	$0.00	$6.3 K	$746.1 K
NEOSTEM (NBS) Andrew Pecora CVO	2013	$221.5 M	$365.0 M	$0.00	$286.5 K	$0.00	$0.00	$873.0 M
	2012	$183.0 M	$0.00	$0.00	$61.7 K	$0.00	$0.00	$244.9 K
	2011	$174.2 K	$0.00	$0.00	$688.7 K	$0.00	$0.00	$863.0 K
NEOSTEM (NBS) Douglas Lesordo CMO	2013	$291.5 K
NEURALSTEM (CUR) I. Richard Garr CEO	2013	$407.0 K	$244.2 K	$0.00	$407.0 K	$0.00	$6.0 K	$1.06 M	$1.30 - $4.80	$317.6 M
	2012	407.00	$195.3 K	$0.00	$407.0 K	$0.00	$6.0 K	$1.0 M
	2011	$407.0 K	$73.2 K	$0.00	$512.8 K	$0.00	$6.0 K	$999.0 K
NEURALSTEM (CUR) Karl Johe CSO	2013	$422.1 K	$253.2 K	$0.00	$2.3 M	$0.00	$6.0 K	$3.0 M
	2012	$422.1 K	$253.2 K	$0.00	$1.8 M	$0.00	$6.0 K	$2.5 M
	2011	$422.1 K	$253.2 K	$0.00	$422.1 K	$0.00	$6.0 K	$1.1 M
NORTHWEST BIO (NWBO) Linda Powers CEO	2013	$360.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$360.0 K	$3.10 - $3.64	$330.5 M
	2012	$360.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$360.0 K
	2011	$203.3 K	$0.00	$0.00	$9.2 M	$0.00	$0.00	$9.4 M
NORTHWEST BIO (NWBO) Alton Boyton CSO	2013	295.60	$0.00	$0.00	$0.00	$0.00	$0.00	$295.60
	2012	$295.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$295.0 K
	2011	$334.7 K	$0.00	$0.00	$1.5 M	$0.00	$0.00	$1.8 M
NORTHWEST BIO (NWBO) Anthony Maida COO	2013	$300.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$300.0 K
	2012	$300.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$300.0 K
	2011	$160.3 K	$0.00	$0.00	$814.1 K	$0.00	$0.00	$974.5 K
NORTHWEST BIO (NWBO) Leslie Goldman Sr. VP	2013	$348.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$348.0 K
	2012	$348.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$348.0 K
	2011	$149.0 K	$0.00	$0.00	$1.4 M	$0.00	$0.00	$1.6 M
NORTHWEST BIO (NWBO) Marnix Bosch CTO	2013	325.20	$0.00	$0.00	$0.00	$0.00	$0.00	$325.20
	2012	$325.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$325.0 K
	2011	$339.3 K	$20.0 K	$0.00	$1.1 M	$0.00	$0.00	$1.5 M
ORGANOVO (ONVO) Keith Murphy CEO	2012	$298.8 K	$0.00	$680.0 K	$0.00	$90.6 K	$0.00	$1.0 M	$3.64 - $13.65	$523.3 M
	2011	$217.7 K	$30.0 K	$0.00	$0.00	$0.00	$0.00	$247.7 K
	2010	$110.0 K	$0.00	$0.00	$0.00	$0.00	$0.00	$110.0 K
ORGANOVO (ONVO) Barry Michaels CFO	2012	$241.8 K	$0.00	$1.2 M	$234.4 K	$73.9 K	$0.00	$1.8 M
ORGANOVO (ONVO) Barry Michaels CFO	2011	$74.3 K	$25.0 K	$0.00	$0.00	$0.00	$0.00	$99.3 K
ORGANOVO (ONVO) Sharon Presnell EVP/R&D	2012	$253.2 K	$0.00	$0.00	$303.9 K	$77.5 K	$0.00	$634.8 K
ORGANOVO (ONVO) Sharon Presnell EVP/R&D	2011	$157.3 K	$50.0 K	$0.00	$54.6 K	$0.00	$24.6 K	$286.7 K
ORGANOVO (ONVO) Eric David C. Strat Off.	2012	$160.9 K	$22.5 K	$0.00	$757.7 K	$47.4 K	$28.2 K	$1.0 M
ORGANOVO (ONVO) Michael Renard EVP/OPS.	2012	$159.9 K	$0.00	$0.00	$758.9 K	$46.2 K	$40.0 K	$1.0 M
OPEXA (OPXA) Neil Warma CEO	2013	$396.5 K	$0.00	$53.7 K	$92.3 K	$0.00	$0.00	$542.6 K	$1.25 - $3.70	$39.5 M
	2012	$396.5 K	$50.0 K	$0.00	$688.6 K	$0.00	$0.00	$1.1 M
	2011	$385.0 K	$50.0 K	$0.00	$115.0 K	$0.00	$0.00	$550.0 K
OPEXA (OPXA) Donna Rill SVP/OPS	2013	$240.0 K	$22.0 K	$37.8 K	$34.3 K	$0.00	$0.00	$334.0 K
	2012	$220.0 K	$15.0 K	$0.00	$154.1 K	$0.00	$0.00	$389.4 K
	2011	$200.0 K	$15.0 K	$0.00	$38.3 K	$0.00	$0.00	$253.3 K
OPEXA (OPXA) Karthik Radhakrishnan CDO	2013	$220.0 K	$10.0 K	$0.00	$154.1 K	$0.00	$0.00	$384.2 K
OPEXA (OPXA) Karthik Radhakrishnan CDO	2011	$200.0 K	$15.0 K	$0.00	$38.3 K	$0.00	$0.00	$253.3 K
OSIRIS (OSIR) C. Randall Mills FORMER CEO	2013	`$434.8 K	$0.00	$0.00	$120.0 K	$0.00	$0.00	$554.8 K	$10.00 - $27.40	$535.6 M
	2012	$470.0 K	$120.0 K	$0.00	$0.00	$0.00	$0.00	$590.0 K
	2011	$470.0 K	$120.0 K	$0.00	$146.6 K	$0.00	$0.00	$736.4 K
OSIRIS (OSIR) Philip Jacoby Jr. CFO	2013	$207.3 K	$20.0 K	$0.00	$80.0 K	$0.00	$0.00	$419.0 K
	2012	$193.0 K	$18.0 K	$0.00	$52.0 K	$0.00	$0.00	$263.0 K
	2011	$189.1 K	$18.0 K	$0.00	$73.2 K	$0.00	$0.00	$280.3 K
OSIRIS (OSIR) Lode Debrabandere COO	2013	$316.7 K	$50.0 K	$0.00	$120.0 K	$0.00	$20.0 K	$507.0 K
	2012	$292.2 K	$35.0 K	$0.00	$65.0 K	$0.00	$0.00	$392.2 K
	2011	$286.6 K	$35.0 K	$0.00	$91.5 K	$0.00	$0.00	$412.5 K
OSIRIS (OSIR) Michelle Williams CSO	2013	$278.8 K	$40.0 K	$0.00	$100.0 K	$0.00	$0.00	$554.8 K
	2012	$271.5 K	$35.0 K	$0.00	$65.0 K	$0.00	$0.00	$371.5 K
	2011	$266.0 K	$35.0 K	$0.00	$91.5 K	$0.00	$0.00	$392.5 K
PLURISTEM (PSTI) Zami Aberman CEO	2013	$489.9 K	$75.0 K	$1.0 M	$0.00	$0.00	$21.0 K	$1.6 M	$2.47 - $4.63	$237.7 M
	2012	$495.6 K	$0.00	$899.5 M	$0.00	$75.0 K	$21.7 K	$1.4 M
	2011	$383.0 K	$0.00	$900.9 K	$0.00	$0.00	$21.6 K	$1.3 M
PLURISTEM (PSTI) Yaky Yanay CFO	2013	$251.3 K	$75.0 K	$770.0 K	$0.00	$0.00	$27.9 K	$1.1 M
	2012	$251.7 K	$0.00	$642.5 K	$0.00	$50.1 K	$27.2 K	$973.6 K
	2011	$200.7 K	$0.00	$629.4 K	$0.00	$0.00	$31.7 K	$861.9 K
PROTEONOMIX (PROT) Michael Cohen CEO	2011	$250.0 K	$75.0 K	$0.00	$0.00	$0.00	$40.0 K	$365.0 K
PROTEONOMIX (PROT) Michael Cohen CEO	2010	$250.0 K	$75.0 K	$0.00	$0.00	$0.00	$40.0 K	$365.0 K
STEMCELLS (STEM) Martin McGlynn CEO	2013	$548.5 K	$287.4 K	$1.2 M	$0.00	$0.00	$43.30	$2.1 M	$0.03 - $0.30	$237.3 K
	2012	$550.0 K	$202.1 K	$430.3 K	$0.00	$0.00	$50.5 K	$1.2 M
	2011	$525.0 K	$187.6 K	$194.0 K	$0.00	$0.00	$48.8 K	$955.5 K
STEMCELLS (STEM) Ann Tsukamoto EVP	2013	$330.0 K	$127.3 K	$515.2 K	$0.00	$0.00	$27.0 K	$999.5 K
	2012	$335.0 K	$84.0 K	$137.8 K	$0.00	$0.00	$26.4 K	$583.2 K
	2011	$300.0 K	$78.0 K	$0.00	$0.00	$0.00	$24.4 K	$402.4 K
STEMCELLS (STEM) Stewart Craig EVP	2013	$298.5 K	$114.0 K	$512.4 K	$0.00	$0.00	$34.2 K	$959.1 K
	2012	$300.0 K	$77.0 K	$137.8 K	$0.00	$0.00	$29.8 K	$544.6 K
	2011	$275.0 K	$71.5 K	$0.00	$0.00	$0.00	$27.8 K	$374.3 K
STEMLINE (STML) Ivan Bergstein CEO	2013	$449.7 K	$321.1 K	$1.2 M	$0.00	$916.4 K	$0.00	$2.9 M	$12.10 - $27.25	$192.7 M
	2012	$350.0 K	$0.00	$0.00	$396.4 K	$0.00	$0.00	$746.4 K
	2011	$350.0 K	$0.00	$0.00	$175.8 K	$0.00	$0.00	$525.8 K
STEMLINE (STML) Eric Rowinsky EVP	2013	$341.7 K	$175.0 K	$1.9 M	$0.00	$277.5 K	$191.6 K	$2.0 M
	2012	$250.0 K	$0.00	$0.00	$918.5 K	$0.00	$0.00	$1.1 M
	2011	$41.6 K	$0.00	$0.00	$0.00	$0.00	$0.00	$41.6 K
STEMLINE (STML) Stephen Hall Former CAO	2013	$227.0 K	$0.00	$995.2 K	$0.00	$72.0 K	$0.00	$1.3 M
STEMLINE (STML) Stephen Hall Former CAO	2012	$25.0 K	$0.00	$0.00	$0.00	$0.00	$32.0 K	$57.0 K
STEMLINE (STML) David Gionco CAO	2013	0.00	$0.00	$0.00	$0.00	$0.00	$13.0 K	$13.0 K
STEMLINE (STML) Kenneth Hoberman COO	2013	$364.6 K	$187,5 K	$0.00	$0.00	$283.4 K	$0.00	$834.4 K
TENGION (TNGN) John Miclot CEO	2013	$462.3 K	$0.00	$0.00	$0.00	$209 K	$39.0 K	$709.9 K	$0.15 - $1.39	$1.2 M
	2012	$450.0 K	$0.00	$224.4 K	$159.9 K	$202.5 K	$100.6 K	$1.1 M
	2011	$34.0 K	$0.00	$0.00	$224.0 K	$0.00	$0.00	$258.1 K
TENGION (TNGN) Timothy Betram CSO	2013	$380.8 K	$0.00	$0.00	$0.00	$137.4 K	$0.00	$518.2 K
	2012	$373.4 K	$0.00	$92.2 K	$77.7 K	$133.4 K	$0.00	$626.9 K
	2011	$316.1 K	$0.00	$96.8 K	$98.4 K	$79.5 K	$1.3 K	$592.2 K
TENGION (TNGN) A. Brian Davis CFO	2013	$336.6 K	$0.00	$0.00	$0.00	$112.6 K	$26.6 K	$475.9 K
	2012	$319.4 K	$0.00	$43.8 K	$36.5 K	$100.4 K	$0.00	$554.3 K
	2011	$292.8 K	$0.00	$56.4 K	$57.0 K	$72.2 K	$0.00	$478.9 K
VISTAGEN (VSTA) Shawn Singh CEO	2013	$201.6 K	$0.00	$0.00	$802.4 K	$0.00	$0.00	$1.0 M	$0.25 - $0.89	$15.9 M
VISTAGEN (VSTA) Shawn Singh CEO	2012	$292.2 K	$0.00	$0.00	$108.5 K	$0.00	$230.1 K	$630.4 K
VISTAGEN (VSTA) H. Ralph Snodgrass CSO	2013	$203.0 K	$0.00	$0.00	$534.9 K	$0.00	$0.00	$738.0 K
VISTAGEN (VSTA) H. Ralph Snodgrass CSO	2012	$249.4 K	$0.00	$0.00	$105.6 K	$0.00	$100.0 K	$455.0 K
VISTAGEN (VSTA) Jerold Dotson CFO	2013	$97.2 K	$0.00	$0.00	$134.3 K	$0.00	$62.3 K	$293.9 K
VISTAGEN (VSTA) Jerold Dotson CFO	2012	0.00	$0.00	$0.00	$108.5 K	$0.00	$71.2 K	$179.8 K
VERASTEM (VSTM) Robert Forrester CEO	2013	$443.8 K	$0.00	$0.00	$2.1 M	$248.0 K	$15.5 K	$2.8 M	$7.10 - $18.82	$207.2 M
	2012	$364.4 K	$0.00	$1.5 M	$0.00	$190.0 K	$14.0 K	$2.1 M
	2011	$252.7 K	$0.00	$35.8 K	$0.00	$130.0 K	$7.0 K	$425.6 K
VERASTEM (VSTM) Daniel Paterson VP/DEV	2013	$314.7 K	$0.00	$0.00	$513.0 K	$150.4 K	$12.5 K	$990.6 K
VERASTEM (VSTM) Daniel Paterson VP/DEV	2012	$244.6 K	$0.00	$1.26 M	$0.00	$116.0 K	$10.2 K	$1.6 M
VERASTEM (VSTM) Joanna Horobin CMO	2013	$350.0 K	$0.00	$0.00	$0.00	$169.0 K	$13.6 K	$532.6 K
VERASTEM (VSTM) Joanna Horobin CMO	2012	$59.2 K	$0.00	$0.00	$1.3 M	$20.0 K	$322.00	$1.33 M

Coverage Ticker

ONCE, PFE
AST 3.98
ATHX 2.59
AXGN 3.17
BLCM 23.22
BHRT 0.01
BLFS 1.93
BRTX 0.46
BTX 4.20
BLUE 95.32
BCLI 4.25
CAPR 5.82
ICEL 5.43
KOOL 0.91
CYTX 1.12
FATE 4.98
FCSC 4.87
HART 3.67
HSGX 10.67
IMUC 0.57
ISCO 0.06
ISTO 0.00
JUNO 46.92
KITE 65.44
MBLTY 16.19
MDXG 10.35
NBS 3.76
CUR 3.76
NWBO 7.37
NUOT 0.26
OCAT 7.22
OPXA 0.79
ONVO 5.92
OSIR 17.27
PSTI 3.04
RENE.L 3.38
STEM 1.12
STML 15.19
VSTM 7.44
VCEL 3.60
VSTA 8.00

Search form

Subscribe for Full Access

Subscribers

Top Sections:

Hold

Sell

Hold

Sell

Sell

Hold

Buy

Buy

Hold

Hold

Hold

Sell

Hold

Hold

Hold

Sell

Sell

Hold

Hold

Hold

Buy

Buy

Hold

Sell

Buy

Hold

Sell

Hold

Sell

Buy

Hold

Buy

Sell

Hold

Sell

Sell

Hold

Buy

Scoreboard

The Scorecard is a performance management tool which can be used by investors to keep track of the execution of activities and to monitor the consequences arising from these actions.

“Cash is king" is an acute expression used in analyzing the RegMed universe to the importance of operating funds available in the development and trial process and the overall fiscal health of a business.

An earnings release is a ‘scorecard’ of sorts for a public regenerative medicine company.

An earnings release is a ‘scorecard’ of sorts for a public regenerative medicine company.

An earnings release is a ‘scorecard’ of sorts for a public regenerative medicine company.

An earnings release is a ‘scorecard’ of sorts for a public regenerative medicine company.

Coverage Ticker